Healthcare for People Who Inject Drugs:  Assessing Engagement and Unmet Need by Heidari, Omeid
Healthcare for People Who Inject Drugs:  









A dissertation submitted to Johns Hopkins University in conformity 
















© 2020 Omeid Heidari  
All Rights Reserved 
 ii 
Abstract 
Background: People who inject drugs (PWID) are an aging population with complex health 
needs. Multimorbidity is common and under addressed. Studies with PWID have shown that 
increases in the number of multimorbidity that were undiagnosed or undertreated, suggesting that 
care needs of this group are complex and impact healthcare utilization. Compounding this, 
PWID utilize healthcare at low rates, and care engagement is understudied. Lack of engagement 
in healthcare increases cost and worsens outcomes. However, no study to date has examined the 
impact of multimorbid chronic diseases on healthcare engagement for PWID and the holistic 
care needs of this population. Through an explanatory sequential mixed-methods study this 
research was designed to explore the healthcare needs of current and former PWID and how they 
engage in healthcare. 
Methods: Guided by the Behavioral Model for Vulnerable Populations (BMVP), this 
dissertation includes a systematic review of literature followed by an explanatory-sequential 
mixed methods study. The quantitative aim was a secondary analysis from the AIDS Linked 
Intravenous Experience (ALIVE) cohort, followed by qualitative interviews with ALIVE 
participants. Latent class analysis (LCA) was used to identify classes of multimorbid chronic 
diseases and explore the degree to which individual characteristics and level of substance use 
was associated with class membership.  Data from LCA informed purposive recruitment for 
qualitative interviews from each class. Qualitative descriptive method was applied for thematic 
analysis using the Behavioral Model for Vulnerable Populations as a conceptual framework.  
Results: Dissertation  findings include identification of complex healthcare needs for this 
population, the role of those needs on healthcare engagement, and can be applied to directions 
for future research, interventions, and policies. Healthcare need was characterized as three 
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distinct classes of multimorbidity found with latent class analysis, each with its own implications 
for healthcare utilization and engagement. Findings from quantitative and qualitative analysis 
showed health insurance status did not serve as a barrier to healthcare access, with almost 
ubiquitous coverage in this post-ACA era study. While continuity of care was not associated 
with any class of multimorbidity, participant interviews highlighted that patient-provider 
relationship, strengthened by integrated care, were important for healthcare engagement. 
Additionally, a subset of participants described the benefits obtained from focused case 
management for wrap-around services, particularly those with co-occurring mental health 
disorder. Thematic analysis from this class also highlighted the importance of mental health 
stability as a means for management of substance use or recovery and other chronic diseases. 
Finally, quantitative and qualitative analysis showed prescription of MOUD linked with certain 
multimorbid classes, highlighting this as an important contributor to healthcare engagement.  
Conclusions: Multiple avenues for healthcare engagement, including positive patient-provider 
relationship, sustained health insurance, alignment of their healthcare needs with those 
designated by healthcare providers, and receiving integrated care to address pressing health 
needs among PWID. Policy considerations include the continued provision of low barrier access 
to publicly available insurance, passage of legislation that provides funding for clinics to provide 
wrap-around services to individuals with substance use disorder, and removal of MOUD 
prescription barriers impacting this at-risk population. Finally, this study affirms the importance 
of healthcare meeting the needs of this population at the level they are able to accept care. 
Holistic healthcare systems can address these needs best with integrated care systems that 
include harm reduction, are co-located with substance use and mental health treatment, and wrap 
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CHAPTER 1: Introduction 
People who inject drugs (PWID) are an aging population, with complex health needs. 
Treatment guidelines and healthcare services designed to provide care to adults who inject drugs 
often limit the scope of their guidelines to infectious disease treatment and prevention, soft tissue 
infections, and harm reduction, with little attention paid to engagement in healthcare for 
treatment of chronic diseases (Centers for Disease Control and Prevention, 2012; Low et al., 
2016; Visconti, Sell, & Greenblatt, 2019). However for PWID, multimorbidity, defined as 
presence of two or more co-occurring diseases, is common and under addressed (Johnston, 
Crilly, Black, Prescott, & Mercer, 2019). This definition of multimorbidity developed with a 
patient centered lens whereby the quality of the diagnosed multimorbid diseases affect physical 
functioning and overall quality of life (Boyd, Cynthia M., Fortin, 2010; Giovannetti et al., 2013). 
A random sample of patients attending a methadone dispensing primary care clinic found 
that 91% of individuals had at least one chronic illness (mean of 2.6); 68% of individuals 
receiving methadone were prescribed at least one additional medication for management of their 
chronic illness (Cullen, O’Brien, O’Carroll, O’Kelly, & Bury, 2009). Individuals receiving 
methadone had 4.4 times higher odds of having a documented chronic illness (Cullen et al., 
2009). Data from a community cohort of current and former PWID in Baltimore, the AIDS 
Linked Intravenous Experience (ALIVE) study, found high prevalence of diabetes (8%), 
obstructive lung disease (19%), liver disease (22%), kidney dysfunction (27%), and hypertension 
(38%) (Salter, Lau, Go, Mehta, & Kirk, 2011). Increases in the number of multimorbid diseases 
in this study population were largely undiagnosed or undertreated, suggesting that care needs of 
this group are complex and impact healthcare utilization (Piggott et al., 2013, 2016; Salter et al., 
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2011). Additionally, no study to date has examined the implications of multimorbidity for 
healthcare engagement for PWID. 
Gruman and colleagues (2010) define engagement in healthcare as, “actions individuals 
must take to obtain the greatest benefit from the healthcare available to them.” Increased 
healthcare engagement leads to improved health outcomes for substance use disorder and 
reduced cost to health systems (Chi, Parthasarathy, Mertens, & Weisner, 2011; Park, Cheng, 
Samet, Winter, & Saitz, 2015; Sujaya Parthasarathy, Chi, Mertens, & Weisner, 2012). However, 
PWID utilize healthcare at low rates compared to those who did not injection drugs and are often 
seen in later stages of disease (Artenie et al., 2015; Larney et al., 2017; Mizuno et al., 2015; 
Okeke, Ostermann, & Thielman, 2015; Oramasionwu, Moore, & Toliver, 2014; Osilla et al., 
2011; Strathdee, Shoptaw, Dyer, Quan, & Aramrattana, 2012; Thompson, Mugavero, Amico, & 
Cargill, 2018; Westergaard, Hess, Astemborski, Mehta, & Kirk, 2013). Limited access and 
barriers that exist within the healthcare infrastructure drive this lack of engagement. Insurance 
status, sex, lack of health insurance, poor provider continuity, active substance use, and stigma 
are predictors of poor utilization and healthcare engagement (Hartzler et al., 2018; Westergaard 
et al., 2013; Westergaard, Kirk, Richesson, Galai, & Mehta, 2011). Still, several factors improve 
healthcare access and engagement. Medication for opioid use disorder (MOUD), integrated care 
services, and focused retention interventions have a positive association with engagement in care 
(Islam et al., 2013; Jack, Willott, Manners, Varnam, & Thomson, 2009; Mehta et al., 2015; 
Miller et al., 2018; Morozova, Dvoriak, Pykalo, & Altice, 2017; Parmenter et al., 2013; Wang et 
al., 2013). Lack of engagement in healthcare increases cost and worsens outcomes. Multiple 
studies have shown the cost effectiveness of managing substance use disorder in the primary care 
setting with implications of improved physical and mental health outcomes, as well as decreased 
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substance use (Babor, Mcree, Kassebaum, Grimaldi, & Ahmed, 2007; Krupski et al., 2016;  
Parthasarathy, Mertens, Moore, & Weisner, 2003; Parthasarathy, Weisner, Hu, & Moore, 2001). 
However, no study to date has examined the impact of multimorbid chronic diseases on 
healthcare engagement for PWID and the holistic care needs of this population.  
Conceptual Framework 
 
This project will utilize the Behavioral Model for Vulnerable Populations (BMVP), an 
adapted framework from the Andersen Healthcare Utilization Model. The first iteration utilized 
three domains associated with an individuals’ likeliness to utilize health care services: 
Predisposing, Enabling, and Need (Andersen, 1968). Later updates to the model included Health 
Behaviors that also influence health care utilization (Andersen, Davidson, & Baumeister, 2013). 
Finally, this model was adapted to include domains specific to its use with vulnerable 
populations (Gelberg, Andersen, & Leake, 2000).  
Predisposing characteristics primarily include demographic data of age, sex, race, and 
education. Enabling variables include income, employment status, and insurance coverage. From 
Need, the presence or absence of the diseases, will be the source of multimorbid disease classes 
from latent class analysis (Table 3). Finally, Health Behaviors are patterns of substance use. 
Figure 1 displays how this project will utilize elements of the Predisposing, Enabling, Need and 
Health Behavior domains for to guide data collection and analysis of the proposed aims. 
Purpose and Specific Aims 
 
This study was designed then with the following overarching research question:  




Through an explanatory sequential mixed-methods study this research will explore the healthcare 
needs of current and former PWID and how they engage in healthcare. The specific aims of this 
study were to: 
Aim 1: Assess current evidence to identify the barriers and facilitators to healthcare 
engagement for the population of PWID with continued active injecting.  
Aim 2:  
 
Characterize the classes and predictors of multimorbid non-communicable and 
communicable chronic diseases among PWID using latent class analysis. We will 
then examine the relationship between classes of multi-morbid chronic diseases 
with individual characteristics and patterns of substance use.   
Aim 3:  
 
Understand the barriers, facilitators, challenges faced, and resources utilized for 
healthcare engagement among ALIVE participants from each multimorbid latent 
class.    
This dissertation includes a systematic review of literature, a secondary analysis of data 
from the ALIVE cohort (PI: Shruti Mehta), and in-depth qualitative interviews with ALIVE 
participants. Latent class analysis (LCA) will facilitate the identification of multimorbid chronic 
disease classes and testing the degree to which individual characteristics and level of substance 
use predicts class membership.  Data from the latent class analysis and the Behavioral Model for 
Vulnerable populations will inform the field guide for the qualitative interviews. Participants 
from each latent class identified in aim 2 will be the recruited for participation in aim 3.  
The proposed research examines engagement in healthcare for substance use treatment 
and underlying multimorbid chronic diseases and will lay the foundation for a career as a 
clinician-scientist dedicated to mitigating the harms of substance use within the primary care 
setting. The proposed aims are closely aligned with NIDA’s Services Research Branch priorities 
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as its findings have direct implications for improving healthcare for multimorbid chronic 
diseases, substance use treatment, continuity of care, and informing integration models for 
PWID. Findings from this study will inform interventions and integrated care systems that 
reduce drug use, provide a pathway to cessation or avenues for harm reduction, and address 
chronic disease diagnosis and long-term management.  
Methodology: Parent Study 
 
The parent study, the AIDS Linked Intravenous Experience (ALIVE) cohort, is the 
longest running prospective cohort with current and former PWID and funded by NIDA. Its three 
aims are: (1) monitor temporal trends in the opioid epidemic comparing HIV infected and 
uninfected PWID across the lifespan, including characterization of shifting drug profiles and 
context over time and their impact on the incidence of fatal and non-fatal overdose; (2) to 
evaluate the dynamic associations between HIV care outcomes and prevalence and control of 
NCDs (e.g., diabetes, hypertension, chronic obstructive pulmonary disease) and impact on 
morbidity, mortality and quality of life (QOL); and (3) to provide a platform for independently-
funded investigations of HIV and drug use. The parent study enrolled a representative sample of 
current and former injection drug users. Study participants commonly refer potential participants. 
Inclusion criteria into ALIVE are: 1) age >=18 years and 2) reporting injection drug use in the 
last year. The only exclusion is not being able to provide informed consent. Table 1 shows 
demographics of individuals currently under follow-up. 
Organization of the Dissertation 
 
There are 5 chapters in this dissertation; chapters 2-4 are formatted as manuscripts for 
publication. Chapter 1 introduces the dissertation and provides background information relevant 
to the study purpose, conceptual framework, and aims of the dissertation.  
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Chapter 2 is a systematic review of literature with the purpose assessing current evidence 
to identify the barriers and facilitators to healthcare engagement for the population of PWID with 
continued active injecting. Findings highlight key areas for care engagement for this population 
but also the difficulty of quantifying outcomes of engagement in care. Future studies should 
consider an adapted framework of the Behavioral Model and multiple outcomes to quantify 
engagement in healthcare.  
Chapter 3 presents the findings from Aim 2. Using data from 604 ALIVE participants, 
latent class analysis identified three classes of multimorbidity: Low Multimorbidity, 
Multimorbidity, and Multimorbidity with Psychiatric Comorbidity. In regression analysis using 
Low Multimorbidity as the reference group, individuals in the Multimorbidity class were more 
likely to receive disability and were less likely to inject drugs. Individuals in the Multimorbidity 
with Psychiatric Comorbidity class were more likely to be female, receive disability, and have 
low income. Compared to the Low Multimorbidity class, individuals in the Multimorbidity and 
Multimorbidity with Psychiatric Comorbidity were more likely to utilize outpatient healthcare 
services, with the later group also more likely to utilize emergency room services.  
Chapter 4 presents the findings from Aim 3. A total of 24 interviews were conducted with 
individuals from each multimorbid class. Thematic analysis was conducted using the domains of 
the BMVP. A priori and in vivio themes in each of the domains demonstrated areas of 
engagement in care that can inform clinical practice, policy, and future research for engaging 
PWID in care specifically and for each multimorbid latent class specifically.  
Chapter 5 synthesizes the findings of the dissertation. Lessons learned from the study are 
discussed, along with implications of the results, situated within the study’s strengths and 
limitations, for better engaging PWID in healthcare.   
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People who inject drugs (PWID) have similar or even increased burden of multi-morbid chronic 
diseases compared to the general population. However, little attention has been paid to the 
engagement of this population in primary care for services related specifically to their injection 
drug use as well as management of their underlying chronic co-morbid diseases. This systematic 
review, utilizing the Behavioral Model for Vulnerable Populations (adapted from the Andersen 
Model for Healthcare Utilization), reviewed evidence related to the engagement of this 
population in the primary care setting and identified facilitators and barriers associated with care 
engagement. Twenty-eight articles were selected using the Preferred Reporting Items for 
Systematic Reviews and meta-Analyses (PRISMA) checklist. Factors of co-location of services, 
case management, active injection, and patient-provider relationship were associated with health 
utilization and engagement. The factors identified can be utilized by future intervention and 
studies to better integrate the care needs of this population holistically in one setting with the 






As a group, individuals who engaged in substance use have a high number of co-
occurring medical conditions.  In a retrospective review of over 800 patients with active 
substance use, Krupski et al (2015) found hypertension (47%), tobacco use (46%), depression 
(43%), hyperlipidemia (24%), HCV (22%), and diabetes mellitus (21%) were among the most 
frequently recorded ICD-9 codes. In a random sample of methadone and non-methadone using 
patients, 91% had at least one listed chronic illness with a mean of 2.6 chronic illnesses 
documented; 68% of individuals receiving methadone were prescribed at least one additional 
medication for the management of their chronic illness (Cullen, O’Brien, O’Carroll, O’Kelly, & 
Bury, 2009). Individuals receiving methadone were at 4.4 times higher odds of having a 
documented chronic illness compared to the non-methadone receiving controls (Cullen et al., 
2009). Further, despite being engaged in care, one longitudinal cohort among people who inject 
drugs (PWID) identifies that individuals with a detectable HIV viral load were also more likely 
to have uncontrolled comorbid diseases like diabetes or hypertension (Monroe, Chander, & 
Moore, 2011). Multimorbid diseases in this population were largely undiagnosed or undertreated 
(Salter, Lau, Go, Mehta, & Kirk, 2011).  
Government organizations and national interest groups concerned with the health and 
well being of this population often limit the scope of their guidelines to harm reduction with little 
attention paid to engagement in primary care. Guidance from the Centers for Disease Control 
and Prevention (CDC) for primary and preventative care with PWID often centers on the 
prevention of infectious diseases, namely Human Immunodeficiency Virus (HIV), Hepatitis C 
(HCV), Hepatitis B (HBV), Sexually Transmitted Infections (STIs), and Tuberculosis (TB) but 
mention the importance of referral and engagement in primary care for integrated services. 
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(Centers for Disease Control and Prevention [CDC], 2012). Their latest guidelines that mention 
engagement of PWID in primary care focuses on delivery of needle exchange programs 
embedded within these sites (CDC, 2015). The Substance Abuse and Mental Health Services 
Administration (SAMHSA) has offered funding to health care organization that integrate mental 
health and primary care but will little attention paid to the at risk group of PWID (Center for 
Mental Health Services, 2015). With the passage of the Comprehensive Addiction and Recovery 
Act (CARA) by Congress in 2016 allowing Nurse Practitioners and Physicians Assistants to 
prescribe medications for opioid use disorder and manage care for PWID, there is increased 
attention to the role primary care can play in managing the holistic care of this population. The 
health care needs of this population clearly lie beyond opioid replacement therapy and sequela 
related to harmful injection practice (deep disuse infection/injury, overdose, etc.) (Nambiar et al., 
2014). Strategies for improving chronic illness identification for PWID as well as for primary 
care interventions that facilitate primary care engagement, adherence and improved outcomes are 
sorely needed.  
The Behavioral Model for Vulnerable populations, adapted from the Andersen Model for 
Healthcare Utilization, examines Predisposing, Enabling, Need, and Health Behavior 
characteristics associated with healthcare utilization and engagement (Andersen, 1968; 
Andersen, Davidson, & Baumeister, 2013; Gelberg, Andersen, & Leake, 2000). Predisposing 
factors are individual characteristics and include age, gender, and relationship status, sexual 
orientation, and substance use. Enabling characteristics are organizational and financing factors 
and include health insurance status, health service resources, and region of residence. Need 
characteristics refer to those that are both perceived by an individual and those evaluated by 
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healthcare providers. Finally, Health Behaviors are those actions taken by PWID that inhibit or 
enable their ability to engage in their healthcare.  
Previous systematic reviews have examined engagement in primary care, one of which 
utilized the Andersen Health Care Utilization model as its theoretical framework (Brennan, 
Morley, O’Leary, Bergin, & Horgan, 2014), yet the review’s inclusion criterion was literature 
with study populations of people living with HIV and determinants related to hospital based 
outpatient care utilization. Islam, et al (2012) conducted a systematic review focused on PWID 
and outpatient care related to models of care delivery and accessibility and acceptability (Islam, 
Topp, Day, Dawson, & Conigrave, 2012).The purpose of this review was to assess current 
evidence to identify the barriers and facilitators to primary care engagement for the population of 
PWID with continued active injecting.  
Methods  
 
 This review utilized the Preferred Reporting Items for Systematic Reviews and meta-
Analyses (PRISMA) checklist for its organization and reported elements (Moher, 2009). 
Searches were conducted in PubMed, CINAHL, and EMBASE using the following combination 
of MeSH (or CINAHL/EMBASE equivalent) and search terms in three topic areas:  
1) Engagement in Care: Patient Participation [Mesh], Patient Acceptance of Health Care 
[Mesh], Patient Compliance [Mesh], engag* [tw], participat* [tw], accept* [tw] or 
involv* [tw] 
2) Intravenous Substance Use: Substance Abuse, Intravenous [Mesh], "iv drug use" [tw], "iv 
drug abuse" [tw], "intravenous drug use" [tw], "intravenous drug abuse" [tw], 
"intravenous drug abuser" [tw], "intravenous drug abusers" [tw], "people who inject 
drugs" [tw], "injection drug user" [tw], or "injection drug users" [tw]  
3) Primary healthcare: "Primary Health Care"[Mesh], "Primary Care Nursing"[Mesh], 
"Physicians, Primary Care"[Mesh], "Nurse Practitioners"[Mesh], "Preventive Health 
Services"[Mesh:NoExp], "Primary Prevention"[Mesh], "Secondary Prevention"[Mesh], 
"Tertiary Prevention"[Mesh], "primary health" [tw], "primary care" [tw], "primary 




Reference lists from studies that met inclusion criteria were also reviewed for additional studies 
that did not turn up in the above search. Quantitative and qualitative studies were considered for 
inclusion.  
 Figure 1 displays the PRISMA consort diagram. A total of 770 articles were found using 
the search terms in PubMed, CINAHL, and EMBASE, 60 of which were duplicates. OH and KT 
screened 710 title and abstracts for relevance. An additional five were included from reference 
lists of articles reviewed in the full text phase. OH and KT reviewed 126 full texts for inclusion, 
with JF breaking a tie in one case of disagreement.  
 Articles that reported a study population made up of PWID and outcomes related to 
engagement in primary care including diagnosis of disease, linkage or retention in care, disease 
related outcomes, or reported patient-provider care preferences, were included in the study. 
Articles with study populations only partially made up of PWID were considered for inclusion if 
they stratified analysis to include effect estimates for PWID. Studies were excluded if they did 
not explicitly measure engagement outcomes with PWID or did not report any domains related to 
engagement in primary care. Additionally, given differences in healthcare delivery and systems, 
study populations outside the United States were excluded. Finally, only data limited to active 
injection (reported injection in the last year) were included in this study; studies reporting a 
history of IDU, or IDU as the transmission factor in the case of HIV and HCV articles, were not 
included.  
The Behavior Model of Healthcare Utilization was used to extract data from selected 
articles. Studies were categorized into factors associated with the predisposing, enabling, need, 
or health behavior domains; studies could straddle these domains based on the factors studied. 
The following definitions were utilized for the three domains of the model: Predisposing 
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characteristics are those existing conditions that are not directly responsible for an individual’s 
decision to engage in care (ex. age, sex, race); Enabling conditions are facilitators or barriers to 
care engagement (ex. stigma, structural barriers, delivery of salient services, etc.) outside the 
individual’s control; Need conditions are divided into actual need (presence of a medical 
condition) and perceived need (the level to which providers recommend and patients desire care 
engagement; Health behaviors included substance use patters and harm reduction uptake as it 
related to engagement and utilization of healthcare (Andersen, 1968; Andersen et al., 2013; 
Gelberg et al., 2000). Data extraction and quality assessments were based on published 





A total of twenty-eight articles were included in the final review. Figure 1 displays the 
number of articles excluded at each stage and the reasons for exclusion. Table 1 displays the 
study characteristics for each included articles. The majority of articles (68%) were rated as 
‘Good’ quality, with nine articles rated as ‘Fair’ or ‘Poor’ (Table 2). The main issue affecting 
methodological quality was lack of information regarding data sources and low-level statistical 
analysis (CRD, 2009; Wong et al., 2008). Table 3 presents a summary of factors associated with 




Two studies measured the impact of sex on engagement outcomes, both related to HIV 
care. When comparing prevalence ratios over time, one study saw increases in uptake in ART for 
both females (aPR 1.15; 95% CI 1.06, 1.24) and males (aPR 1.06; 1.01, 1.10), with females 
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having the higher prevalence ratio (Hoots, Finlayson, Broz, & Paz-Bailey, 2017). In contrast, the 
other study, which reported outcomes stratified by sex and race, found that White females had 
the lowest percentage of person-time in care after ART initiation and that both White and Black 
females had the greatest percentage of person-time in care with a viral load>1,500 copies/mL 
(Lesko, Lau, Chander, & Moore, 2018). The later study, however, only displayed percentages of 
person-time stratified by race and sex with ART and viral load outcomes without conducting 
relevant multivariate analysis or testing for differences between the groups.  
Race and Ethnicity 
Four studies measured race with engagement outcomes. Two studies demonstrated higher 
engagement for Black and Hispanic individuals with an increase in ART at each 3-year reporting 
period (Hoots et al., 2017) and that Hispanic and non-Hispanic Black individuals had greater 
odds of receiving an HIV prevention discussion from their healthcare provider at their most 
recently visit (J. Wilkinson et al., 2006). Additionally, one article with a nationally representative 
cohort of people living with HIV engaged in primary care found that Black PWID were 
significantly less likely to report recent injection drug use (aOR 0.26; 95% CI 0.16, 0.42) 
(Mimiaga et al., 2013). Finally, in contrast to these three, one article reported Black race 
associated with lower odds of utilizing drug treatment (aOR 0.41; 0.21, 0.78) (Riley, Wu, et al., 
2002), though this study was conducted in the setting of a needle exchange. 
Education  
 Results regarding education and engagement were mixed. Two studies demonstrated 
lower education associated with increased engagement outcomes (Hoots et al., 2017; J. 
Wilkinson et al., 2006) while two additional studies found that those with a self-report education 
less than 8th grade had significantly lower odds of engagement behaviors (Barocas et al., 2014; 
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Knowlton et al., 2010). However, while measured outcomes between all four studies differed, it 
is feasible that individuals with lower education had increased access to ART and care over time 
(Hoots et al., 2017; J. Wilkinson et al., 2006) but when compared to those with increased 
education in a cross-sectional analysis, were at lower odds of taking ART (Knowlton et al., 
2010) and reporting HCV testing in the prior year (Barocas et al., 2014).  
Age 
 Using a cutoff of age 50, age groups above and below both had increases in prevalence in 
ART uptake over time, while older age was associated with increased engagement (Hoots et al., 
2017; Knowlton et al., 2010; Riley, Safaeian, et al., 2002). Young individuals were more likely 
to be injecting (Mimiaga et al., 2013) but also had greater adjusted odds of willingness to use 




 Across the five studies that examined the effect of health insurance on a measure of 
engagement in care, all showed a significant positive association. Multiple studies demonstrated 
an increase in primary care and drug treatment utilization, with point estimate odds raging from 
2.00 to 2.58 (Barocas et al., 2014; Riley, Safaeian, et al., 2002; J. D. Wilkinson et al., 2007). 
Additionally, having health insurance was associated with increases in ART uptake (Hoots et al., 
2017; Knowlton et al., 2010). Additionally, one qualitative study also indicated that the high cost 
of healthcare as a salient barrier.  
Co-location of services 
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 Three studies reported quality measurements related to co-location of primary care 
services with another service salient to PWID (i.e. HIV, Hepatitis C treatment, buprenorphine). 
Results were promising with high retention in care (61%) with buprenorphine services offered in 
primary care, high success for hepatitis C treatment (98%) when done with in an opioid 
treatment program, and high uptake of ART (84%), pneumocystis pneumonia prophylaxis 
(77%), and preventative care screenings for PWID living with HIV (Butner et al., 2017; Hersh, 
Little, & Gleghorn, 2011; O’Connor, Molde, Henry, Shockcor, & Schottenfeld, 1992). These 
studies, however, reported on care outcomes without exploring differences by individual or 
structural factors, or selecting comparison groups for a nuanced analysis.  
Patient-provider relationship and stigma 
 The two articles that examined the effect of patient-provider relationship on engagement 
in care both indicated a positive relationship associated with increased engagement while a 
negative relationship adversely effected engagement (Barocas et al., 2014; Knowlton et al., 
2010). Three qualitative articles (Biello et al., 2018; Oliva, Rienks, & McDermid, 1999; Skeer, 
Ladin, Wilkins, Landy, & Stopka, 2018) found that negative experiences with healthcare 
providers a barrier for later accessing care. Biello et al., contextualized the quantitative and 
qualitative findings, demonstrated by the following: 
“The minute [the doctors] find out you are a drug addict, that you are an injection [drug] 
user, you can see it right in their face. They change their whole attitude. They do not want 
to help you...I hate telling the doctor that I use drugs...because they are going to blame 
anything wrong with you on the drug use.”  
 
Case management 
 Two articles demonstrated the positive effect of case management and targeted linkage to 
care on healthcare engagement (Kidorf, King, Gandotra, Kolodner, & Brooner, 2012; J. D. 
Wilkinson et al., 2007). One in particular demonstrated that when combined with a financial 
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incentive, PWID undergoing multiple sessions for linkage to care and treatment readiness were 
more likely to enroll in a drug treatment program (aOR 2.52; 95% CI 1.23- 4.24) and spent more 
days in drug treatment compared those with a standard of care referral (p<0.001); though the 
authors note the difficulty in scaling this linkage to care intervention with an incentive, similar 
significant but attenuated odds were seen when comparing the linkage to care intervention alone 
to standard of care (Kidorf et al., 2012).  
Housing  
Both articles that examined the effect of housing found a deleterious effect of 
homelessness on engagement in care (Knowlton et al., 2010; Liappis, Laake, & Delman, 2014). 
Among those living with HIV, those actively engaged in injection drug use were more likely to 
report homelessness compared to those with non-active IDU (p<0.001); active PWID in that 
study were found to have worse health outcomes, even when utilizing HIV primary care (Liappis 
et al., 2014). Conversely, stable housing was significantly associated with uptake of ART 
(Knowlton et al., 2010).  
Peer networks 
Norms within peer group acted as barriers and facilitators to healthcare engagement. Two 
studies demonstrated the positive effect of peers on engagement, one where peers acted as a 
social support during drug treatment and medication adherence (Broadhead et al., 2002) and 
another where norms for safer drug use were associated with decreased odds of sharing injection 
equipment (aOR 0.92; 95% CI 0.86, 0.98) (Latkin et al., 2008). The former study, however, only 
piloted its peer support program with 14 patients and its findings are not generalizable without 
further study. Finally, one qualitative study found among PWID, HIV related stigma within 





 Two studies found significant associations between an increased number of care visits 
and engagement in healthcare (Knowlton et al., 2010; Latkin et al., 2008) with one additional 
study noting that rating HIV care ‘very important’ (aOR 1.77; 1.31, 2.37) and engagement with a 
provider (aOR 1.72; 1.17, 2.57) as significantly associated with an HIV prevention discussion 
with a healthcare provider  (Wilkinson et al., 2006).  When perceptions of healthcare need and 
access were measured, two studies found negative associations with being an active injection 
drug user and difficulty accessing care (Biello et al., 2018; D D Chitwood, McBride, French, & 
Comerford, 1999), with the qualitative study noting a theme of competing healthcare needs and 
priorities related to active drug use and dependence (Biello et al., 2018).  
Actual need  
 In two studies, disease stage was significantly associated with engagement in healthcare, 
where individuals with a CD4 counts <350 more likely to be taking ART at the 6 month follow 
up visit (aOR 1.65; 1.23, 2.22), while those with CD4 counts >= 200 associated with more visits 
with a primary care provider (aOR 1.64; 1.10, 2.46) (Knowlton et al., 2010; Wilkinson et al., 
2007). Both were from the INSPIRE study and the same time period of analysis, though 
measurement of ART outcomes was defined as taking ART at least 1 day in the prior month 
(Knowlton et al., 2010). Five studies measured comorbidities among PWID. Two demonstrated 
PWID more likely to be diagnosed with common infectious and non-infectious chronic diseases 
(Liappis et al., 2014; Mimiaga et al., 2013), with one qualitative study found illness level as a 
major theme, which acted as a barrier to accessing Hepatitis C care (Skeer et al., 2018). The final 
two studies measured syndemic psychological and structural distress without diagnosis of a 
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mental health disorder, finding that higher levels of psychological distress was associated with 
increased sharing of drug paraphernalia and increased number of psychological and structural 
problems significantly associated with not taking ART, poor adherence to ART, and a detectable 
viral load (Latkin et al., 2008; Mizuno et al., 2015).  
Health Behavior  
Ongoing injection drug use  
 Ten studies noted the adverse effect of active injection drug use on engagement in 
healthcare (Brewer et al., 2007; Butner et al., 2017; Chitwood, Sanchez, Comerford, & McCoy, 
2001; Chitwood, Comerford, & McCoy, 2002; Kavasery et al., 2009; Knowlton et al., 2010; 
Marquez, Mitchell, Hare, John, & Klausner, 2009; Mimiaga et al., 2013; Ompad et al., 2004; 
Westergaard, Hess, Astemborski, Mehta, & Kirk, 2013).  While outcomes of engagement in care 
were measured differently, with respect to active injection, three found negative associations 
with ART uptake and adherence (Kavasery et al., 2009; Marquez et al., 2009; Mimiaga et al., 
2013) and another three found decreased healthcare visits and satisfaction (Brewer et al., 2007; 
Chitwood et al., 2001; Chitwood et al., 2002).  
Harm reduction 
Two studies measured harm reduction and healthcare engagement. Exchanging more 
needles was associated with utilization of primary care (Riley, Wu, et al., 2002) while those who 
shared works were significantly more likely to report willingness to use PrEP (Kuo et al., 2016).  
Discussion  
 
 This systematic review sought to determine factors related to engagement in primary care 
for people who inject drugs with active use. Data from articles chosen for review were abstracted 
into factors contained within predisposing, enabling, need, and health behavior domains of the 
  
 28 
Behavioral Model for Vulnerable Populations (Gelberg et al., 2000). To our knowledge this is 
the only review of evidence that examined the factors related to primary care engagement for 
people who inject drugs with active injecting. 
 Two prior systematic reviews have been conducted in this population.  Brennan, et al 
(2014) conducted a systematic review that utilized the Andersen Health Utilization Model among 
people living with HIV utilizing hospital based outpatient services. Another review reviewed 
literature between 2000-2010 and examined models of primary care delivery and acceptability of 
these services by PWID (Islam et al., 2012). Additionally, Visconti, Sell, and Greenblatt (2019), 
published an article related to primary care for people who inject drugs, but did not take a 
systematic approach and only reported clinical care recommendations.  
Many important themes emerged from the synthesis of literature but to varying degrees 
of strength. From the Enabling domain, patient-provider relationship emerged as a strong factor 
related to care engagement where, across all the studies reviewed, positive patient-provider 
relationship was associated with greater engagement with negative relationships associated with 
less engagement. Co-location of services also emerged as a facilitator to primary care 
engagement, but studies associated with this finding were not highly rated due to their 
methodologically poor statistical analysis. Other studies with PWID have also demonstrated that 
medication of opioid use disorder (MOUD) in the primary care setting as a factor correlated to 
engagement in healthcare, though they did not meet criteria for inclusion in this review (Islam et 
al., 2013; Jack, Willott, Manners, Varnam, & Thomson, 2009; McNeil, Small, Wood, & Kerr, 
2014; Mehta et al., 2015; Morozova, Dvoriak, Pykalo, & Altice, 2017; Parmenter et al., 2013; 
Wang et al., 2013). Case management and strong peer support appeared in multiple articles as a 
strong facilitator to engagement in care. Finally, current insurance status was a strong predictor 
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of healthcare engagement across the five studies that measured it, but only two were published 
on data collected after the Affordable Care Act, suggesting that linkage to healthcare insurance, 
rather than access, can be more salient to healthcare engagement with the expansion of health 
insurance.  
Predisposing factors were not well measured or well represented across the studies with a 
few exceptions. Only one study stratified analysis by sex but did not providing proper effect 
estimates (Lesko et al., 2018). As a whole, measures and comparisons of race and ethnicity were 
also inconsistent. While differences in race as a predisposing factor were reported in the results 
section, little can be drawn from them without reported effect estimates. Anrdo- and 
ethnocentrism was evident since many studies had samples that were over 50% male and rarely 
had balance in racial and ethnic groups reported.  
Evidence from the Need domain described the complicated nature of care engagement for 
PWID. Studies demonstrated high burden of multimorbidity, difficulty with accessible healthcare 
services that meet perceived needs, and the competing nature of active substance use with 
engagement in primary care. Health behaviors were most consistently measured across studies, 
with strong evidence for active injecting as a salient barrier to care engagement. This can be an 
area where clinical practice better assess injecting practices and provides harm reduction services 
in the primary care setting (Visconti et al., 2019).   
 There were multiple limitations to this study. Filters on publishing date were not applied 
to this systematic review. This introduces bias as secular changes in healthcare policy and 
service access contribute greatly to healthcare engagement. The majority, 61% of articles,  
included here, were published in the last decade, in the post-Affordable Care Act era. Strict 
inclusion criteria proved limiting as only studies conducted in the United States and with an 
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actively injecting population were included. While this inclusion yielded 28 studies for review, 
many additional studies with potentially relevant finding were excluded because they only 
reported a history of IDU or IDU as a transmission factor only, or were conducted outside the 
United States. Finally, engagement in healthcare as an outcome proved difficult for data 
synthesis, as outcomes for engagement are wider ranging than healthcare utilization measures 
alone. This wider definition, however, allows for more nuanced analysis and understanding of 
healthcare needs for this population. Future studies with PWID will benefit from collecting and 
reporting on active versus historical injection drug use and with a clear conceptual framework for 
healthcare engagement outcomes.  
 In conclusion, several factors were found to be barriers or facilitators to engagement in 
primary care for PWID. With the ongoing opioid epidemic, careful attention should be paid to 
how to engage individuals in the primary care setting for needs outside the traditional infectious 
disease and MOUD areas researched (Nambiar, Stoové, & Dietze, 2014). Clinical practice and 
research should continue to view patients and research participants’ holistic needs rather than the 
sum of their disease parts. While most of the studies here fell under aforementioned areas for 
PWID, the findings and factors associated with the Behavioral Model for Vulnerable Populations 
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Table 2.1 Characteristics of included studies 






(Barocas et al., 
2014) 
PWID utilizing a free syringe 
exchange program  
Mixed methods with 
cross sectional 
quantitative design 







(Biello et al., 
2018) 
HIV uninfected PWID Qualitative Semi structured interviews 2017 33 n/a 
(Broadhead et 
al., 2002) 
PWID living with HIV Intervention feasibility Demographic and selected 
outcomes collected by health 
educator overseeing the study 
1996 14 Up to 14 weeks 
(Brewer et al., 
2007) 
PLWH recently positive with less 
than 1 visit to primary care and not 
initiated ART 
ARTAS randomized 
clinical trial that sought 
to evaluate a case 
management 
intervention  
Baseline ARTAS data May 2001-
May 2002 
282, 31 PWID n/a-  
(Butner et al., 
2017) 
PWID enrolled in an OTP and 
receiving direct acting antiretroviral 
for HCV treatment 
Retrospective program 
evaluation 









Individuals with current IDU, non-
IDU substance use, or nondrug 
users 
Cross sectional Multiple questionnaires 










Individuals with current IDU, non-
IDU substance use, or nondrug 
users 
Cross sectional Multiple questionnaires 











Individuals with IDU, non-IDU 
substance use, or non-drug users 
Cross sectional Multiple questionnaires 






(Hayes et al., 
2014) 
Young PWID enrolled in the UFO 
study consenting to this sub-study 
Cross sectional Questionnaire administered 
by trained study staff and self-
determined HCV test 
2012-2013 127 n/a 
(Hersh et al., 
2011) 
Individuals enrolled in the Office 
based opiate treatment program  
(OBOT) pilot program 
Program evaluation Secure database of data 




57 Up to 12 months 
(Hoots et al., 
2017) 
PWID participating in the National 
HIV Behavior Surveillance (NHBS) 
3 cross-sectional data 
collections 






(Kavasery et al., 
2009) 
PLWH and reporting IDU in the last 
year at baseline 
Longitudinal 
prospective cohort 
AIDS Linked Intravenous 
Experience; biannual data 
collection  
1996-2005 335  Up to 10 years 
(Kidorf et al., 
2012) 
Opioid dependent PWID at a NEP Randomized trial Baseline intervention 
followed by monthly data 
collection visits by study staff 
May 2003-
March 2007 
281  1 years following 
randomization 
(Knowlton et al., 
2010) 
Eligibility criteria included injection 
drug use in the past year, 
willingness to participate in group 
education session, and sex with an 





Data from baseline and 6 
month follow up study visits 




12 months for full 
study but 6 months 
in this analysis  
(Kuo et al., 2016) PWID participating in the National 
HIV Behavior Surveillance (NHBS) 
Surveillance National HIV Behavioral 
Surveillance  
2012 304 n/a 
(Latkin et al., 
2008) 
Eligibility criteria included injection 
drug use in the past year, 
willingness to participate in group 
education session, and sex with an 





Data from baseline, 6 and 12 
month follow up study visits 
2001-2005 966  12 months 
(Lesko et al., 
2018) 
Patients engaged HIV in continuity 
care  
Cohort Medical records 2010-2015 3,021 Up to 6 years 
(Liappis et al., 
2014) 
People living with HIV at a 
Washington DC with a history of or 
ongoing substance use 
Retrospective cohort Electronic medical records 1998-2009 316; 141 PWID Between 6 months 
and 11 years 
(Marquez et al., 
2009) 
PLWH receiving care at one of 
UCSF's HIV primary care clinics 






(Mimiaga et al., 
2013) 
PLWH receiving primary care 
services as part of the Centers for 
AIDS Research Network of 
Integrated Clinical Systems study 
Ongoing observational 
cohort 
CNICS data repository 2005-2010 Model 1: 3, 413 
Model 2: 2,618 




(Mizuno et al., 
2015) 
Eligibility criteria included living 
with HIV, IDU in the past year, 
willingness to participate in group 
education session, and sex with an 
opposite-sex partner in the last 3 
months 
Cross sectional 
analysis of a secondary 
HIV prevention 
intervention study 
Baseline assessment 2001-2005 1,052 n/a 
(O’Connor et al., 
1992) 
PWID receiving clinical care at a 
clinic with co-located drug 
treatment and HIV primary care 
Program evaluation Chart review by clinicians 
who were not the primary care 
provider of the patient under 
study  




(Oliva et al., 
1999) 
Participants were in the 
childbearing population, with the 
majority (77%) reporting injection 
drug use 
Qualitative 6 focus group interviews 1999 63 n/a 
(Ompad et al., 
2004) 
PWID and PWUD from two 
separate ongoing studies in New 
York City susceptible to HBV and 
accepted a referral for HBV 
vaccination  
Prospective cohort Study surveys and vaccination 












et al., 2002) 
 
PWID utilizing a free syringe 













(Skeer et al., 
2018) 
Current or former PWID with self-
reported positive HCV status 





PLWH and reporting IDU in the last 
year at baseline 
Longitudinal 
prospective cohort 
AIDS Linked Intravenous 
Experience; biannual data 
collection by study staff 
1998-2011 790 Up to 13 years 
(Wilkinson et al., 
2006) 
Eligibility criteria included living 
with HIV, IDU in the past year, 
willingness to participate in group 
education session, and sex with an 
opposite-sex partner in the last 3 
months 
Cross sectional 
analysis of a secondary 
HIV prevention 
intervention study 
Baseline assessment 2001-2005 1101 n/a 
(Wilkinson et al., 
2007) 
Eligibility criteria included injection 
drug use in the past year, 
willingness to participate in group 





Data from baseline, 6 and 12 
month follow up study visits 
2001-2005 966  12 months 






































































Figure 2.1   
PRISMA diagram 
of selected studies 
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SE, SD, or 95% 




Generalizability Other quality Issues Overall 
assessment 
of Quality 
(Barocas et al., 
2014) 
Unlikely Unlikely Yes Yes SEP offered to a wide range of urban, 
suburban, and rural populations 
Sampling for qualitative 
interviews not mixed from 
quantitative survey  
Good 
(Biello et al., 
2018) 
Unlikely Unlikely n/a n/a Member checking not done  Good 
(Broadhead et al., 
2002) 
Likely Likely No No Concentrated on 14 individuals with 
clinician assessed poor adherence but 
accessed HIV primary care 
 Poor 
(Brewer et al., 
2007) 
Unlikely Unlikely Yes Yes IDU was not associated with outcome 
in adjusted model 
 Fair 
(Butner et al., 
2017) 
Likely Unlikely No No Analysis limited to only the first 75 



















Unlikely Unlikely Yes Yes Representative sample of an urban 
IDU population 
 Good 
(Hersh et al., 2011) Likely Unlikely No No Demographics not generalizable to 
larger population of PWID 
 Fair 
(Hoots et al., 2017) Unlikely Unlikely Yes Yes National representative sample of 
PWID over three reporting periods 
 Good 
(Kavasery et al., 
2009) 
Unlikely Unlikely Yes  Yes Aging population of PWID in urban 
center 
 Good 
(Kidorf et al., 
2012) 
Unlikely Unlikely Yes No Incentive based referral intervention 
may not be feasible to scale 
 Good 
(Knowlton et al., 
2010) 
Likely Unlikely Yes Yes Individuals recruited from an urban 
centers where HIV primary care 
maybe different 
 Good 
(Kuo et al., 2016) Unlikely Unlikely Yes Yes National representative sample of 
PWID over three reporting periods 
 Good 
(Latkin et al., 
2008) 
Likely Unlikely Yes  Yes Individuals recruited from an urban 





(Lesko et al., 2018) Likely Unlikely No Yes Data stratified by PWID vs non IDU 
but test statistics not reported for 
measures of those actively injecting 
 Fair 
(Liappis et al., 
2014) 
Likely  Unlikely No No This analysis was restricted to those 
actively engaged in HIV care but 
comparisons are between people with 
active IDU to former IDU 
 Fair 
(Marquez et al., 
2009) 
Likely Unlikely Yes No Findings not generalizable to general 
injecting population 
 Fair 
(Mimiaga et al., 
2013) 
Unlikely Unlikely Yes Yes Good study design, though models 
were limited due to low number of 
PWID  
 Good 
(Mizuno et al., 
2015) 
Likely Unlikely Yes  Yes Individuals recruited from an urban 
centers where HIV primary care 
maybe different 
 Good 
(O’Connor et al., 
1992) 
Likely Likely No No Study conducted in a pre-HAART, 
pre-ACA era 
 Fair  
(Oliva et al., 1999) Unlikely Unlikely n/a n/a Member checking not done ` Good 
(Ompad et al., 
2004) 
Likely Unlikely Yes Yes Older study with participants recruited 
from ongoing studies 
Vaccine completion data 
not collected by study staff 
directly  
Good  
(Riley, Safaeian, et 
al., 2002) 
Likely Unlikely Yes Yes Convenience sample of PWID from 
two urban based NEPs 
 Good 
(Skeer et al., 2018) Unlikely Unlikely n/a n/a  Member checking not 
done 
Good 
(Westergaard et al., 
2013) 
Unlikely Unlikely Yes Yes Aging population of PWID in urban 
center 
 Good 
(Wilkinson et al., 
2006) 
Likely Unlikely Yes  Yes Individuals recruited from an urban 




(Wilkinson et al., 
2007) 
Likely Unlikely Yes  Yes  Good 
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Table 2.3 Summary of results of included studies 
Reference Predisposing Enabling Need Health Behaviors 
(Barocas et al., 
2014) 
Education: Completing college or 
technical school associated with 
HCV test in the last year compared 
to lower level of education: 
aOR 1.9 (1.4-2.5).  
Insurance: Having a primary 
care provider (aOR 2.0; 1.3-
3.0) and health insurance 
(p=0.02) associated with HCV 
testing the past year.  
 
Location: Urban and Suburban 
had higher testing in the last 
12m (p=0.05) Milwaukee zip 
code (aOR 2.3; 1.5-3.5).  
 
Relationship: Lack of rapport 
with provider associated with 
not testing (p=0.02). 
Overdose: History of opioid overdose 
associated with HCV testing: aOR 1.8 
(1.1-2.8).  
 
(Biello et al., 
2018) 
Individual level: Barriers included 
low PrEP knowledge and limited 
HIV risk perception 
Relationship Barriers related to 
negative experiences with 
healthcare providers  
 
Stigma: HIV-related stigma 
within social networks 
 
Capacity: Poor infrastructure 
an for PrEP delivery to PWID  
Healthcare need: Competing health 





 Peer support: The results 
suggest that an alternative 
social support structure to drug 
treatment is feasible for 
increasing active drug user's 
adherence to medical care  
  
(Brewer et al., 
2007) 
   IDU: PWID had lower proportions of 
initiating HIV primary care compared 
to non-drug users (p<0.01) but in 
adjusted model injecting not associated 
with initiating HIV primary care 
(Butner et al., 
2017) 
 Co-location: 98% of 
participants completing 
treatment obtained SVR; 99% 
of patients adhered to HCV and 
OTP treatment 
 IDU: Ongoing drug use occurred in 
23% of patients undergoing treatment 
(Chitwood, 
McBride, 
  Healthcare need and access: PWID 







care compared to NDU (aOR1.64; 
1.08-2.50) and no access to care when 






   IDU: Associated with decreased odds 
of receipt of a primary physical 




   IDU: Significantly negatively 
associated with satisfaction with access 
to healthcare in adjusted analysis 
(p<0.001) 
(Hersh et al., 
2011) 
 Co-location: 61% retention in 
care after 1 year at an office 
based buprenorphine program 
 SU: Reduction in toxicology positive 
for opioids from baseline (58%) to 1 
year follow up (14%) 
(Hoots et al., 
2017) 
Prevalence ratios comparing ART 
use per 3-year increase:  
 
Sex: Female (aPR 1.15; 1.06-1.24) 
Male (aPR 1.06 (1.01-1.10) 
 
Race and Ethnicity: Black (aPR 
1.07; 1.02-1.13) Hispanic: aPR 1.10 
(1.02-1.18) 
 
Age: Age<50 (aPR 1.09; 1.02-1.17) 
Age>=50 (aPR 1.07 (1.01-1.12) 
 
Education: HS or less education 
(aPR 1.10; 1.05-1.15) 
Prevalence ratios comparing 
ART use per 3-year increase:  
 
Insurance: Current insurance 
(aPR 1.07; 1.03-1.11) 
  
(Kavasery et al., 
2009) 
   IDU: Daily injecting associated with 
interruption of ART (aOR 1.43; 1.02-
1.98) and early interruption of ART 
(aOR 1.80; 1.04-3.10). Daily or greater 
injecting less likely to restart ART 
(aOR 0.69; 0.49-0.97) 
(Kidorf et al., 
2012) 
 Linkage: PWID in MRC+I 
were more likely to enroll in 
methadone treatment compared 
to MRC only (aOR 2.29; 1.23-
4.24) and SRC (aOR 2.52; 
1.36-4.75); MRC+I were more 
likely to report more days in 
drug treatment compared to 
 IDU: MRC+I were significantly more 
likely to report less heroin use and 
injecting in the last 30 days compared 
to MRC only and SRC (p<0.001) 
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Age: Older age associated with 
taking ART (aOR 1.03; 1.00-1.05) 
 
Education: Self-report education 
<8th grade associated with lower 
odds of taking ART (aOR 0.54; 
0.35-0.85) 








engagement rated as perfect 
(aOR 1.45; 1.09-1.93) 
Disease stage: CD4<350 associated 
with taking ART (aOR1.65; 1.23-2.22) 
 
Care visits: Greater than 4 visits in the 
last 6 months associated with taking 
ART (aOR 1.44; 1.09-1.91) 
SU: Drug use in the last 3 months 
associated with lower odds of taking 
ART (aOR 0.67; 0.50-0.90) 
(Kuo et al., 
2016) 
Age: Younger PWID (<50) were 
more likely to report willingness to 
use PrEP (aOR 3.05; 1.44-6.50) 
  Harm reduction: Those who shared 
works in the last year were 
significantly more likely to report 
willingness to use PrEP (aOR 3.47; 
1.71-5.06);  
(Latkin et al., 
2008) 
 Peers: Norms for safer drug 
use associated with decreased 
odds of sharing injection 
equipment (aOR 0.92; 0.86-
0.98)  
Psychiatric: Higher levels of 
psychological distress associated with a 
greater likelihood of drug paraphernalia 
sharing (aOR 1.34; 1.01-1.79) 
 
Care visit:  HIV primary care visit in 
the last 6 months associated with 
decreased odds of sharing injection 
equipment (aOR0.48; 0.27-0.85) 
 
(Lesko et al., 
2018) 
Sex and race: White females had the 
lowest % time in care post ART 
(88.5%), and both White and Black 
female PWID had the greatest % of 
time in care with viral load >1500 
copies (21.6%) and time in care 
post-ART with a viral load >1500 
copies (White 15.9%; Black 18.7%) 
   
(Liappis et al., 
2014) 
 Housing: Active IDU were 
more likely to report 
homelessness (61%) (p<0.001) 
compared to non-active IDU 
Comorbidities: Active IDU were more 
likely to be smokers (93%) (p<0.001), 
in a methadone program (63%) 
(p<0.001), have comorbid HBV (88%) 
(p<0.001), HCV (95%) (p<0.001), 
Stroke (6%) (p=0.05), DVT/PE (12%) 
(p<0.001), multiple BSI (13%) 
(p<0.02), and less likely to be on ART 




undetectable viral load (31% vs 43% 
(p=0.02) compared to non-active IDU 
 
 
(Marquez et al., 
2009) 
    
 
IDU: The only route of use associated 
with poor adherence in 
methamphetamine users was injection 
(PR: 2.1, 95% CI: 1.0-4.6)  
 
(Mimiaga et al., 
2013) 
Age: PWID were less likely to be 
older (p<0.01) 
Race: PWID were less likely to be 
Black (aOR 0.26; 0.16-0.42) 
 Comorbidities: PWID higher odds of 
major depression (aOR 2.19; 1.75-2.73) 
and report drug treatment (aOR 5.00; 
4.03-6.20) 
IDU: More likely to have a detectable 
viral load (aOR 1.48; 1.15-1.90), 
higher non adherence scores (aOR 
1.44; 1.27-1.63),  
 
(Mizuno et al., 
2015) 
  Report of 1 (aOR 2.03; 1.20-3.43), 2 
(aOR 2.07; 1.24-3.44), 3 (aOR 2.79; 
1.63-4.78), and 4-6 (2.47 (1.41-4.30) 
problems  (vs. no problems) were all 
associated with not currently taking 
HIV medication. 3 problems (aOR 
3.34; 1.01-5.42) and 4 problems (aOR 
2.56; 1.07-2.63) were associated with 
non-adherence to HIV medication 
(<90%) in the previous day); 4 
problems was associated with a 
detectable HIV viral load (aOR 2.24; 
1.18-4.27) 
Those with 3 problems (aOR 2.12; 
1.16-3.89) and 4 problems (aOR 4.85; 
2.62-9.00) were more likely to reports 
sharing works with HIV negative or 




 Co-location: PWID enrolled in 
the CMU had high uptake of 
ART (84%), prophylaxis for 
pneumocystis pneumonia 
(77%), and screening for TB 
(87%), Syphilis (100%), and 
Hepatitis B (100%) 
  
(Oliva et al., 
1999) 
 Healthcare barriers identified: 
The high cost of health care, 
perceived poor quality of care 
and experiences of 
discrimination and 
stigmatization, geographic 
accessibility, fear of 
legal/social services punitive 
actions 
  
(Ompad et al., 
2004) 
   IDU: Daily injectors (42%) and 
injectors in the last 6 months (42%) 
were less likely to initiate the vaccine 
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series (p=0.03); 16% of daily and 36% 
of injectors in the last 6 months were 
less likely to complete vaccine series 
(p=0.02) compared to non-injectors. 
Daily injectors were less likely to 
complete the vaccine series (aOR 0.28; 
0.09, 0.88) 
(Riley, Safaeian, 
et al., 2002) 
Age: Older age (>39) was associated 
with primary care utilization in the 
last 3 years (aOR 1.82; 1.09-3.05) 
 
Race: Black race associated with 
lower odds of utilizing drug 
treatment in the last 3 years (aOR 
0.41; 0.21-0.78)  
 
Employment: Unemployment 
associated with higher odds of drug 
treatment in the last 3 years (aOR 
2.72; 1.08-6.84)  
Insurance: Associated with 
primary care utilization in the 
last 3 years (aOR 2.16; 1.20-
3.86) and drug treatment in the 
last 3 years (aOR 2.05; 1.19-
3.56) 
 Harm reduction: Exchanging more 
than 7.5 syringes per NEP visit was 
associated with primary care utilization 
in the last 3 years (aOR 2.45; 1.46-
2.33) 
(Skeer et al., 
2018) 
 Themes regarding social 
determinants of engagement in 
HCV treatment 
Themes regarding illness level for 





   IDU: Injection associated with lapses 
in HIV care (aOR 1.25; 1.06-1.49) and 




Race and Ethnicity: Hispanic (aOR 
2.28; 1.37-3.82) and non-Hispanic 
Black (aOR 2.22; 1.71-2.89) 
compared to non-Hispanic Whites 
Education: High school or less 
education (aOR 1.86; 1.27-2.72), 
were more likely to report a 
prevention discussion at the most 
recent care visit 
 Care visits: Rating HIV care very 
important (aOR 1.77; 1.31-2.37) and 
engagement with a provider (aOR 1.74; 





Self efficacy: Increase in importance 
of HIV care scale score (OR = 5.65; 
P = 0.01) increased empowerment 
(OR = 2.42; P = 0.005), taking 
greater control of one’s health (OR = 
2.17; P = 0.001), were significantly 
associated with reporting 2 or more 
primary HIV care visits in the past 6 
months. 
 Health insurance: Associated 
with primary HIV care visits 
(OR = 2.58; P = 0.003) 
 
Case management: Associated 
with primary HIV care visits 
(OR = 3.14; P = 0.027) 
Disease stage: CD4 count <200 
cells/mm3 (OR = 2.09; P = 0.007) was 
significantly associated with primary 
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People who inject drugs (PWID) are an aging population, with complex health needs. Care for 
multimorbid diseases may be complicated by ongoing substance use and inconsistent access to 
health care in this population. However, little is known about multimorbidity and its effect on 
healthcare engagement for this population. The purpose of this study is to characterize classes of 
multimorbidity for a population of PWID, identify the individual, health behavior, and structural 
characteristics associated with each multimorbidity class, and determine the relationship of these 
classes with healthcare utilization and health event outcomes. We found three classes of 
multimorbidity: Low Multimorbidity, Multimorbidity, and Multimorbidity with Psychiatric 
Comorbidity. Nearly 75% of the sample fell into the classification of having Multimorbidity or 
Multimorbidity with Psychiatric Comorbidity. Individuals in each of these groups had extremely 
high conditional probabilities of all of the diseases we considered with the key distinction of 
additional psychiatric comorbidity in one group. These groups were significantly more likely to 
receive disability and had higher healthcare utilization than the Low Multimorbidity group. While 
these findings are not unexpected, there are resulting consequences for the health care system 
and the affected individuals. Holistic healthcare systems can address these needs best with 
integrated care systems that provide for harm reduction, co-location with substance use and 







People who inject drugs (PWID) are an aging population, with complex health needs. 
Treatment guidelines and healthcare services designed to provide care to adults who inject drugs 
often limit the scope of their guidelines to infectious disease treatment and prevention, soft tissue 
infections, and harm reduction, with little attention paid to engagement in healthcare for 
treatment of chronic diseases (Centers for Disease Control and Prevention, 2012; Low et al., 
2016; Visconti, Sell, & Greenblatt, 2019). However, for PWID, multimorbidity, defined as 
presence of two or more co-occurring diseases, is common and under addressed (Johnston, 
Crilly, Black, Prescott, & Mercer, 2019).  Data from a community cohort of current and former 
PWID in Baltimore, the AIDS Linked Intravenous Experience (ALIVE) study, found high 
prevalence of diabetes (8%), obstructive lung disease (19%), liver disease (22%), kidney 
dysfunction (27%), and hypertension (38%) (Salter, Lau, Go, Mehta, & Kirk, 2011). Moreover, 
these conditions co-occurred in 58% of PWID. Multimorbid diseases in this study population 
were largely undiagnosed or undertreated, suggesting that care needs of this group are complex 
and impact healthcare utilization (Piggott et al., 2013, 2016; Salter et al., 2011).  
Gruman and colleagues (2010) define engagement in healthcare as, “actions individuals 
must take to obtain the greatest benefit from the healthcare available to them.” Increased 
healthcare utilization leads to improved health outcomes for substance use disorder and reduced 
cost to health systems (Chi, Parthasarathy, Mertens, & Weisner, 2011; Park, Cheng, Samet, 
Winter, & Saitz, 2015; Parthasarathy, Chi, Mertens, & Weisner, 2012). However, PWID utilize 
outpatient healthcare at low rates, emergency and inpatient care at higher rates, and are often 
seen in later stages of disease (Artenie et al., 2015; Larney et al., 2017; Mizuno et al., 2015; 
Okeke, Ostermann, & Thielman, 2015; Oramasionwu, Moore, & Toliver, 2014; Osilla et al., 
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2011; Strathdee, Shoptaw, Dyer, Quan, & Aramrattana, 2012; Thompson, Mugavero, Amico, & 
Cargill, 2018; Westergaard, Hess, Astemborski, Mehta, & Kirk, 2013). Limited access and 
barriers that exist within the healthcare infrastructure drive this lack of engagement. Insurance 
status, sex, lack of health insurance, poor provider continuity, active substance use, and stigma 
are predictors of poor utilization and healthcare engagement (Hartzler et al., 2018; Westergaard 
et al., 2013; Westergaard, Kirk, Richesson, Galai, & Mehta, 2011).  
On the flip side, there are a number of factors that have been demonstrated to facilitate 
healthcare access and engagement. Medication for opioid use disorder (MOUD), integrated care 
services, and focused retention interventions have a positive association with engagement in care 
(Islam et al., 2013; Jack, Willott, Manners, Varnam, & Thomson, 2009; Mehta et al., 2015; 
Miller et al., 2018; Morozova, Dvoriak, Pykalo, & Altice, 2017; Parmenter et al., 2013; Wang et 
al., 2013). However, no study to date has examined the impact of multimorbid chronic diseases 
on primary care engagement for PWID.  
Latent Class Analysis (LCA) is a useful method to highlight nuanced patterns of 
multimorbidity by exploring how diseases co-occur among PWID (Lanza & Rhoades, 2011). 
Additionally, this method can show associations of individual, structural, and health behavior 
characteristics with underlying multimorbidity classes, which have implications for engagement 
in care (Lanza & Rhoades, 2011). The Behavioral Model for Vulnerable Populations, adapted 
from the Andersen Model of Healthcare Utilization, was selected as the framework for this 
analysis. The model posits Predisposing, Enabling, Need, and Health Behavior based factors that 
influence primary care utilization and engagement (Andersen, 1968; Gelberg, Andersen, & 
Leake, 2000), which were used to guide LCA, its interpretation, and to position finding’s 
implications for care.  
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Using classes of multimorbid diseases to build understanding of holistic healthcare needs, 
it is possible to inform interventions and integrated care systems that reduce drug use, provide a 
pathway to cessation or avenues for harm reduction, and address chronic diseases. The purpose 
of this study was to characterize classes of multimorbidity for a population of PWID, identify the 
individual, health behavior, and structural characteristics associated with each multimorbidity 
class, and determine the relationship of these classes with healthcare utilization and health event 




 Data were derived from the AIDS Linked Intravenous Experience (ALIVE), a 
population-based cohort study with current and former people who inject drugs in Baltimore, 
MD. The ALIVE study was first established in 1988 to characterize the incidence and natural 
history of HIV among PWID (Vlahov et al., 1991). Subsequent recruitment waves of new 
participants occurred during 1994-1995, 1998, 2005-2008, and 2015-2018. Eligibility criteria 
included being 18 years or older and a history of injection drug use. Participants underwent 
biannual visits with an interview, clinical examination, and biospecimen collection. All 
participants provided written informed consent prior to participation in the study. The Johns 
Hopkins Bloomberg School of Public Health Institutional Review Board approved study 
procedures. This analysis utilized data collected between 2014-2018. Participants with at least 
one study visit in 2014 and 2018 were included. Across the 9 possible study visits between the 
January 2014 and June of 2018, participants included in the final analysis had a mean of 8 visits 
(Std. Dev. 1.06). Of the 921 individuals with at least one study visit in 2014, 604 had a study by 
the end of June 2018, and were included in this analysis. Compared to those included in analysis, 
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those who only had a study visit in 2014 were significantly less likely to report a baseline 
emergency room visit  (p=0.006) and less likely to be Black race (92% vs. 84%; p<0.001) but 
were otherwise similar on other characteristics of sex and baseline income, disability status, 
outpatient healthcare utilization, insurance, and substance use.  
Communicable Disease Indicators 
Indicators for latent class analysis were the presence or absence of chronic diseases 
commonly treated in the outpatient clinical setting.. Individuals were classified as ever having 
each disease based on responses at the longitudinal study visits using the established criteria 
described below: 
Arthritis: Self-report of diagnosis of or treatment for arthritis at a study visit during a study visit 
between 2014-2018.  
Anxiety/Depression: Self-report of diagnosis or treatment for anxiety at any study visit between 
2014-2018, or a Centers for Epidemiologic Studies Depression Scale (CES-D) score of 23 or 
greater at two or more study visits, indicating persistent major depressive symptoms (Carleton et 
al., 2013).    
Diabetes: Self-report of medications for diabetes or a Hemoglobin A1c (HbA1c) value 6.5% or 
greater for any specimen collected between 2014-2018.  
Hypertension: Self-report of medications for hypertension at any visit or blood pressure readings 
of systolic>= 140 or diastolic>=90 at two or more study visits between 2014-2018.  
Human Immunodeficiency Virus: Self-report of antiretroviral therapy (ART) at any visit or 
confirmed HIV antibody at any study visit through 2018, including those before 2014.  
Liver Fibrosis (Severe and Cirrhotic): Based on the median value of liver stiffness from transient 
elastography (FibroScan) measurements taken at each study visit between 2014-2018. 
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Participants were classified based on cutoffs for F3 severe fibrosis (kPa >=9.5) or F4 cirrhosis 
(kPa>=12.5) (Kirk et al., 2009), and collapsed into one dichotomous variable.  
Major Psychiatric Disorders: Self-report of medications or diagnosis for bipolar disorder, 
schizophrenia, or schizoaffective at a study visit between 2014-2018.  
Obstructive Airway Disease: Ratio of the forced expiratory volume in 1 second to forced vital 
capacity of <=70% at two or more study visits between 2014-2018.  
Renal Dysfunction: Self-report of treatment for renal dysfunction or an estimated glomerular 
filtration rate <60 mL/min/1.73 m2 using the MDRD equation at any study visits between 2014-
2018. 
Covariates associated with class membership 
 Covariates were selected based on characteristics described by Behavioral Model for 
Vulnerable Population as salient to healthcare utilization and engagement.  
Predisposing 
Baseline age: Measured as a continuous variable at the first study visit in 2014 and transformed 
into a dichotomous variable. We split the variable near the median age of this study sample, 55 
years old.  
Sex: A dichotomous variable comparing self-report male vs. female sex.  
Race: Classified as Black compared to non-Black race.  
Enabling 
Baseline income: Measured as a dichotomous variable at the first study visit in 2014 comparing 
individuals with an annual income less than $5,000 dollars per year to those with an income 
greater than $5,000 per year.  
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Baseline disability: Measured as a dichotomous variable at the first study visit in 2014 based on 
the following question: “Currently, are you receiving SSI (Supplemental Security Income) or 
SSDI (Social Security Disability Income), or any other type of disability?” 
Baseline insurance: Self-report health insurance in the last six months at the first study visit in 
2014 
Continuity of care: Self-report of healthcare visits with the same healthcare provider for the last 
2 years at the first visit in 2014  
Health Behaviors 
Baseline substance use: To capture substance use and route of administration, we combined 
baseline self-report of heroin, cocaine, crack, and/or speedball in the last 6 months into the 
following categories: Injection only, non-injection only, both injection and non-injection, with no 
substance use as the reference category. 
Baseline alcohol use: Binary variable for self-report of any alcohol use in the last 6 months.  
Baseline cigarette use: Binary variable for self-report of any cigarette use in the last 6 months.  
Health events and healthcare utilization 
Infectious events: Self-report of diagnosis or treatment for sepsis, pneumonia, endocarditis or 
skin infection in the last 6 months at a study visit between 2014-2018 
Cardiovascular events: Self-report of diagnosis or treatment for myocardial infarction, heart 
failure, heart disease, or stroke in the last 6 months at a study visit between 2014-2018 
Emergency room visit: Self-report of utilization of emergency room services in the last six 
months at the last study visit in 2018 
Outpatient visit: Self-report of utilization of outpatient healthcare services in the last 6 months at 
the last study visit in 2018 
  
 59 
Medication for opioid use disorder:  Self-report of prescription of buprenorphine, naltrexone, or 
methadone in the last 6 months at the last study visit in 2018 
Statistical analysis 
 
 Data cleaning and variable transformation as well as logistic regression to examine the 
effect of multimorbid disease class on healthcare utilization and health events was conducted in 
Stata 16 (StataCorp, 2019). Latent class analysis and predictors of regressions to classify 
predictors of class membership were conducted using Mplus Version 8 software (Muthen & 
Muthen, 2011). LCA was used to explore underlying classes of multimorbid disease clustering. 
The Akaike Information Criteria (AIC), Bayesian Information Criteria (BIC), sample size 
adjusted Bayesian Information Criteria (aBIC), Lo-Mendell-Rubin adjusted likelihood ratio test 
(LMR-LRT), and Bootstrapped likelihood ratio test were utilized to evaluate the optimal number 
of multimorbid diseases classes (Nylund, Asparouhov, & Muthen, 2007). Conditional 
probabilities for each disease indicator specify the probability of presence of that disease for the 
given class (Nylund et al., 2007). Interpretability of the classes based on the conditional 
probabilities of disease indicators and entropy of class membership were also considered in 
selecting the final class structure (Celeux & Soromenho, 1996).  
Following the identification of the optimal number of classes, predisposing, enabling, and 
health behavior characteristics were included as covariates with unadjusted regression using the 
R3STEP function in MPlus, which examines that covariate’s correlation with a multimorbidity 
class, relative to a reference class. The reference for all models was the class with the lowest 
percent of multimorbid diseases. A priori variables of age, sex, insurance, and substance use 
were selected for the final adjusted model regardless of statistical significance based on the 
conceptual framework (Gelberg et al., 2000).  Additionally, enabling variables with statistically 
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significant unadjusted associations (p<0.02) with either class were selected for the adjusted 
model. Finally, the effects of multimorbid class on dichotomous outcomes of healthcare 
utilization and health events were examined using logistic regression, controlling for associated 
predisposing and enabling characteristics.  
Results 
 
Demographic characteristics  
 Of the 604 individuals included in this analysis, the majority were male sex (65%) and 
Black race (92%). At baseline, the mean age was 54 years old (IQR=8.6). Less than half reported 
an annual income greater than $5,000 (34%), and a high percentage reported filing for disability 
(84%). Only 5% of the study sample reported being uninsured in the last 6 months at baseline, 
with 70% reporting coverage with Medicare or Medicaid. At baseline, 38% of this study 
population reported substance use in the previous 6 months, with equal proportions reporting 
non-injection use only (43%) or both injection and injection use (42%); only a small proportion 
of those reporting substance use at baseline used injection drugs exclusively (14%). Almost a 
quarter of the participants reported using emergency room services in the previous 6 months and 
three quarters utilizing outpatient healthcare services. Finally, at the first visit in 2014, 70% of 
participants had evidence of two or more multi-morbid diseases used as indicators for latent class 
analysis.  
Model Selection 
 A comparison of model fit indices indicated that a three-class solution was optimal 
(Table 2). HIV was the only disease indicator dropped from analysis, as its conditional 
probabilities were similar in each class; model fit and interpretability improved with its 
exclusion. Additionally, HIV and viral load status were examined as covariates of class 
  
 61 
membership, but neither was associated with class membership. Information criteria (AIC, BIC, 
and aBIC) were lowest for a three-class solution. Additionally, the LMR/LTR and Bootstrapped 
LRT indicated a three-class solution significantly improved fit compared to two classes, and fit 
did not significantly improve when adding a fourth class (Nylund et al., 2007). A three-class 
solution and its interpretability highlighted the following patterns of multimorbidity classes: 
Class 1 (Low Multimorbidity), Class 2 (Multimorbidity), and Class 3 (Psychiatric Comorbidity). 
Class 3 was the largest with 42% (N=251) of the participants, followed by Class 2 (N=190, 31%) 
and Class 1 (N=163, 27%).  
Latent Class Analysis  
 Table 3 lists the percent of people with of each disease indicator for the three 
multimorbid classes based on the percentage. Across the three classes, there were similar 
conditional percentages of obstructive airway disease. The Low Multimorbidity class (Class 1) 
had a high conditional probability of hypertension as well (67%), but this was still substantially 
lower than the probability of hypertension in the Multimorbidity class (93%) and Multimorbidity 
with Psychiatric Comorbidity class (83%). The Multimorbidity class had higher percentage of all 
diseases compared to the other two classes except for the two psychiatric indicators. In 
particular, individuals in the Multimorbidity class had substantially higher probability of severe 
liver fibrosis/cirrhosis compared to the Multimorbidity with Psychiatric Comorbidity class (53% 
vs. 42%) and the Low Multimorbidity class (53% vs. 31%). This Multimorbidity class also had 
markedly higher probabilities of diabetes compared to the other two classes, with a 32-
percentagentage point higher probability compared to the Low Multimorbidity class (36% vs. 
4%). The Multimorbidity with Psychiatric Comorbidity class had distinct probabilities of major 
psychiatric disorder and anxiety/depression. There was a 100% probability of anxiety and/or 
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depression for individuals in this class, which was approximately 80-percentage points higher 
than the Multimorbidity and Low Multimorbidity classes. This class also had a 79% probability 
of a major psychiatric disorder (bipolar disorder or schizophrenia), 63 percentage points higher 
than the Low Multimorbidity class (16%) and 67 percentage points higher than the 
Multimorbidity class.  
Baseline correlates of class membership  
 Table 4 shows the correlates of class membership relative to class 1, Low Multimorbidity. 
The Low Multimorbidity class did not differ from either of the other two classes on race, baseline 
continuity of care with a provider, alcohol, and cigarette use in bivariate analyses and these 
variables were not included in the final model. In unadjusted models, individuals in the 
Multimorbidity class were significantly more likely to be receiving disability at baseline and be 
insured compared to individuals in the Low Multimorbidity class. In the adjusted model, 
individuals in the Multimorbidity class had 5.9 higher odds of baseline disability (95% CI 2.36-
14.54) compared to the Low Multimorbidity class. Additionally, individuals in the 
Multimorbidity class in the adjusted model were significantly less likely to report injecting drugs 
compared to the Low Multimorbidity class (aOR 0.16 95% CI 0.03-0.99). Individuals in the 
Multimorbidity with Psychiatric Comorbidity class were significantly more likely to be female 
than the Low Multimorbidity class (aOR 5.75 95% CI 1.65-20.13). Similar to the Multimorbidity 
class, persons in the Multimorbidity with Psychiatric Comorbidity class had significantly higher 
unadjusted and adjusted odds of baseline disability compared to the Low Multimorbidity class 
(aOR 7.7 95% CI 3.2-18.7). Finally, those in this class had 2 times higher odds of a baseline 
income less than $5,000 (95% CI 1.12-3.99) but this did not retain statistical significance in the 
adjusted model.   
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Differences in healthcare utilization and health events 
 Table 5 displays odds ratios of associations between class membership and healthcare 
utilization and health event outcomes, using the Low Multimorbidity class as the reference and 
controlling for baseline age, sex, race, income, disability, care continuity, and substance use in 
the adjusted logistic regression model. Compared to those in the Low Multimorbidity class, 
persons in the Multimorbidity with Psychiatric Comorbidity class had significantly higher odds 
of an infectious disease health event (OR 1.88; 95% CI 1.21-2.91), but this did not retain its 
statistical significance in the adjusted model (aOR 1.56; 95% CI 0.97-2.52). Individuals in the 
Multimorbidity with Psychiatric Comorbidity class had significantly higher adjusted odds of 
emergency room visits (aOR 1.77; 95% CI 1.03-3.02) compared to the Low Multimorbidity class. 
Persons in the Multimorbidity with Psychiatric Comorbidity class (aOR 1.76; 95% CI 1.04-2.98) 
and Multimorbidity class (aOR 2.00; 95% CI 1.15-3.49) both had significantly higher odds of 
outpatient healthcare utilization compared to the Low Multimorbidity class. Finally, those in the 
Multimorbidity with Psychiatric Comorbidity had significantly higher odds of a prescription for 




 Our study identified three distinct classes of multimorbidity in an aging cohort of current 
or former PWID. Moreover, nearly 75% of the sample were classified as having Multimorbidity 
or Multimorbidity with Psychiatric Comorbidity. Individuals in each of these two groups had 
very high co-occurring probabilities of all of the diseases we considered with the key distinction 
of additional psychiatric comorbidity in one group. These groups were significantly more likely 
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to receive disability, and had higher healthcare utilization, while, while not unexpected, had 
consequences for the healthcare system and these individuals. 
 Multiple studies have examined  multimorbidity profiles in the general aging population 
using this approach (Gellert et al., 2019; Hall et al., 2018; Hustoft et al., 2013; Islam et al., 2014; 
Olaya et al., 2017; Park, Lee, & Park, 2019; Whitson et al., 2016). While those studies and this 
differ in their selection and measurement of diseases, their findings, like ours, demonstrated 
heterogeneity in multimorbidity. Two studies (Gellert et al., 2019; Olaya et al., 2017)  noted 
increased utilization of healthcare services by latent classes with increased multimorbid diseases; 
one study (Whitson et al., 2016) also noted differential utilization of healthcare services by 
multimorbidity class. Their findings, however, still confirm the heterogeneity of multimorbidity 
and associated characteristics, allowing for nuanced understanding of multimorbidity with 
implications for future interventions.  
 The Low Multimorbidity class was the smallest of the three described here. This class has 
been described as the “healthy” class in previous studies (Islam et al., 2014; Larsen, Pedersen, 
Friis, Glumer, & Lasgaard, 2017; Olaya et al., 2017; Park et al., 2019; Whitson et al., 2016) due 
to its low probability of all diseases under study. While set as the reference group for analysis of 
associations with class membership, this class was significantly more likely to be uninsured in 
unadjusted analysis with the other two classes. This association was not noted in other studies, 
though many of were conducted in settings outside the United States with universal healthcare 
coverage. Therefore, health insurance was not considered. Longitudinal analyses within ALIVE 
have previously demonstrated that health insurance coverage was associated with significantly 
increased prescription of medication for opioid use disorder and continuity with a healthcare 
provider (Feder et al., 2019). Additionally, this class had a high probability of hypertension 
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(67%) compared to other studies (Islam et al., 2014; Larsen et al., 2017; Olaya et al., 2017; Park 
et al., 2019). The absence of a class with low probabilities of all diseases might be related to our 
selection criteria of individuals having at least two of the selected diseases as an inclusion 
criterion. Given this and the high probabilities of severe liver fibrosis (31%) and obstructive 
airway (31%) compared to the national prevalence, there is still a demonstrated need for this 
population to be engaged in regular care with semi-annual or annual health assessments and 
screenings (Singal et al., 2009; Visconti et al., 2019).  
 The Multimorbidity class was the second largest and was characterized by high 
probabilities of all non-psychiatric diseases. The disease makeup of this class could not be 
directly compared with other published studies as their multimorbidity classes provided more 
granular identification of classes based on specific diseases due to their higher sample sizes 
(Islam et al., 2014; Larsen et al., 2017; Olaya et al., 2017; Park et al., 2019; Whitson et al., 
2016).  Previous studies with this cohort also demonstrated the decreased odds of injection drug 
use with increased multimorbidity (Salter et al., 2011). The decreased odds of injecting for this 
group could be related to the increased utilization of outpatient care, though only the association 
of active injection on lower utilization has been previously demonstrated (Maragh-Bass, Powell, 
Park, Flynn, & German, 2017). The increased odds of outpatient healthcare utilization by this 
class were also seen in similar classes with multimorbidity that did not include a psychiatric 
comorbidity (Gellert et al., 2019; Olaya et al., 2017; Whitson et al., 2016). Taken together, the 
Behavioral Model would indicate alignment of perceived and actual healthcare need, as 
participants in this class were more likely to utilize outpatient healthcare services in the last six 
months compared to the Low Multimorbidity class, which had a decreased perceived and actual 
need (Gelberg et al., 2000).  
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 The Multimorbidity with Psychiatric Comorbidity was the largest class with similar high 
disease probabilities to the Multimorbidity class, but unique with its high probabilities of major 
psychiatric disorders and anxiety/depression. While measured inconsistently across studies, 
analyses that included at least one mental health diagnosis noted one distinct class with a 
psychiatric co-morbidity (Islam et al., 2014; Larsen et al., 2017; Olaya et al., 2017; Park et al., 
2019). This class was the only one significantly associated with a predisposing characteristic, 
female sex (aOR 5.75; p<0.001). This was also noted in national reporting of mental health 
disorders with women having higher prevalence of any mental illness, depression/anxiety, and 
severe mental illness (Bose, Hedden, Lipari, & Park-Lee, 2018). The Multimorbidity with 
Psychiatric Comorbidity was also notable for being the only class associated with an infectious 
disease event between 2014-2018 in bivariate analysis, though significance was lost in the 
adjusted model. Additionally, this class had much higher odds of all measures of healthcare 
utilization. It was the only class with higher odds of receipt of MOUD and outpatient healthcare 
utilization. Other studies with PWID have also demonstrated co-location of MOUD with primary 
and outpatient care as a factor correlated to engagement (Islam et al., 2013; Jack et al., 2009b; 
McNeil, Small, Wood, & Kerr, 2014; Mehta et al., 2015; Morozova, Dvoriak, Pykalo, & Altice, 
2017b; Parmenter et al., 2013b; Wang et al., 2013). Structurally, multiple studies have also 
documented the increase in receipt of medication for opioid use disorder following passage of 
the Patient Protection and Affordable Care Act, especially for states which expanded Medicaid 
services (Feder et al., 2017; Tormohlen et al., 2019). Participants in this class benefit from 
expansion of healthcare and guaranteed coverage of MOUD services in this legislation. Finally, 
while this class had the highest odds of outpatient care and MOUD utilization, it was the only 
class also associated with emergency room utilization. This may indicate unmet need, possibly 
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related to one of the psychiatric co-morbidities (Gelberg et al., 2000). One study determined 
severity of mental health disorders significantly associated with increased utilization of 
emergency room services (Niedzwiecki, Sharma, Kanzaria, McConville, & Hsia, 2018) with 
another systematic review showing that attempted suicide or self-harm as potential drivers of this 
utilization (Barratt et al., 2016). Based on our data and available evidence, closer follow up with 
individuals in this class with integrated mental health with other outpatient healthcare services, 
including wrap-around case management, would be most appropriate. 
 There are limitations to this study. While diseases are measured over a five-year period 
and most with a physiological or biological marker to confirm diagnosis, there were still some 
disease states that were classified by self-report alone. This is particularly a limitation with 
severe psychiatric disorders, though classification was based on self-report of diagnosis or 
prescription of a medication. There was also overlap with measurement of diseases over the five-
year period and the healthcare utilization and health event data, limiting the temporality of 
associations. However, this study’s purpose was to determine the holistic needs of an aging 
population of PWID rather than to infer causality of multimorbidity class on healthcare 
engagement. Our study’s restriction to participants with study visits in 2014 and first visit in 
2018 limited the sample size, though sensitivity analysis with all participants with a 2014 visit 
only also indicated a similar 3 class structure of multimorbidity. Latent class analysis and finite 
mixture modeling can be useful tools in determining heterogeneity of multimorbidity, but future 
studies should attempt to select diseases and classify their states based on an established 
criterion. One study utilized the Charlson Comorbidity Index when selecting diseases and its 
measurement, a potential standard for future comorbidity studies (Islam et al., 2014). Because 
this data was from an aging population of largely Black, male, and urban population, its findings 
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are not generalizable to the larger population of PWID. Future studies should attempt to classify 
based on severity of disease states and utilize longitudinal data to determine how classes of 
multimorbid disease management change over time. 
 As a current or former PWID seek healthcare, their needs extend beyond the traditional 
realms of substance use. This study demonstrates heterogeneity in multimorbidity for PWID with 
distinct latent classes. Two of these classes of multimorbidity indicate greater healthcare need 
and a need for interventions to improve engagement. Additionally, there is a large subsample of 
the population that has an even greater need for care due to co-occurring mental health disorders. 
Clinicians can capitalize on the characteristics and implications for each class, tailoring follow-
up and care services to clearly address the needs of multimorbidity classes. Holistic healthcare 
systems can address these needs best with integrated care systems that provide for harm 
reduction, co-location with substance use and mental health treatment, and wrap around services, 
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Table 3.1 Study sample baseline characteristics, 604 ALIVE participants with a study 
visit in 2014 and 2018.  
 
Predisposing characteristics 
Age, median (range) 54 (28-
73) 
Female sex 212 (35%) 
African-American race 556 (92%) 
 
Enabling characteristics 
Annual income < $5,000 398 (66%) 
Disability  508 (84%) 
Insurance last 6 months 571 (95%) 
Same provider the last 2 years 376 (63%) 
 
Health behaviors: Substance use in the last 6 months  
Any drug use* 228 (38%) 
Injection drug use only 33 (5%) 
Non-injection only  98 (16%) 
Both injection and non-injection  97 (16%) 
Alcohol 300 (50%) 
Cigarettes 458 (76%) 
 
Healthcare utilization in the last 6 months 
Emergency Room Visit  142 (24%) 
Outpatient Clinic Visit 465 (77%) 
Medication for Opioid Use Disorder   
(Methadone, Buprenorphine, Naltrexone) 
235 (39%) 
 
Need characteristics: Comorbidity prevalence 
HIV 192 (32%) 
Diabetes 89 (15%) 
Hypertension 387 (64%) 
Renal Disease 42 (7%) 
Arthritis 197 (33%) 
Major Psychiatric comorbidity (Bipolar or Schizophrenia) 160 (26%) 
Anxiety/Depression  212 (35%) 
Fibrosis (F3/F4)** 113 (25%) 
Obstructive Airway Disease*** 94 (20%) 
*Injection or non-injection use of heroin, cocaine, crack, and/or speedball  
** Fibroscan available for 444 individuals in 2014 






Table 3.2 Latent Class Model Fit Statistics of 8 disease indicators, from a sample of 
ALIVE participants (n=604) from 2014-2018 
Model Log-
Likelihood 





1 -3100.7 6219.4 6259.1 6230.4    
2 -3004.6 6047.2 6130.8 6070.5 0.75 0.000 0.000 
3 -2809.8 5671.7 5786.2 5703.6 0.65 0.04 0.000 
4 -2957.2 5992.5 6164.2 6040.4 0.67 0.31 0.67 
Table 3.3 Latent classes of multimorbidity classified by individual disease indicators, 
n=604 ALIVE participants from 2014-2018 














No 99% 42% 41% 
Yes 1% 58% 59% 
Major Psychiatric Disorders (Bipolar and Schizophrenia) 
No 84% 88% 21% 
Yes 16% 12% 79% 
Anxiety/Depression  
No 77% 79% 0% 
Yes 23% 21% 100% 
Diabetes 
No 96% 64% 77% 
Yes 4% 36% 23% 
Liver Fibrosis (Severe and Cirrhotic) 
No 69% 47% 58% 
Yes 31% 53% 42% 
Hypertension 
No 33% 7% 17% 
Yes 67% 93% 83% 
Obstructive Airway 
No 69% 69% 70% 
Yes 31% 31% 30% 
Renal Dysfunction 
No 97% 70% 76% 




Table 3.4 Estimates of class membership with baseline characteristics (relative to low multimorbidity class), n=604 ALIVE 
participants from 2014-2018 
Class Multimorbidity 
Multimorbidity including psychiatric 
comorbidity 
Covariate  OR (95% CI) aOR (95% CI) OR (95% CI) aOR (95% CI) 
Predisposing characteristics 
Age >55 years  1.62 (0.82-3.18) 1.25 (0.56-2.80) 0.57 (0.31-1.04) 0.55 (0.26-1.17) 
Female 2.57 (0.95-6.96) 2.99 (0.79-11.31) 5.60 (2.32-13.53) 5.75 (1.65-20.13) 
African-American 1.32 (0.30-5.88)  0.48 (0.15-1.48)  
Baseline enabling variables  
Income < $5,000/year 0.80 (0.41-1.60) 0.67 (0.28-1.57) 2.12 (1.12-3.99) 1.58 (0.69-3.63) 
Disability 3.02 (1.45-6.27) 5.86 (2.36-14.54) 4.34 (2.26-8.35) 7.73 (3.20-18.67) 
Insurance (last 6 
months) 5.89 (2.04-16.95) 3.67 (0.92-14.65) 5.89 (2.04-16.95) 5.27 (0.75-37.20) 
Continuity of care 1.07 (0.54-2.14)  1.10 (0.60-1.99)  
Baseline health behaviors: Substance use in the last 6 months 
Injection only 0.67 (0.19-2.42) 0.16 (0.03-0.99) 1.53 (0.57-4.06) 0.55 (0.15-2.05) 
Non-injection only  0.49 (0.18-1.34) 0.76 (0.13-4.43) 1.59 (0.76-3.30) 2.73 (0.56-13.27) 
Both injection and 
non-injection  0.67 (0.19-2.42)  0.97 (0.25-3.70) 1.53 (0.57-4.06) 2.69 (0.84-8.62) 
Alcohol 0.85 (0.43-1.65)  1.07 (0.60-1.91)  
Cigarettes 0.61 (0.28-1.31)  2.04 (0.96-4.32)  
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Table 3.5 Association between class membership on healthcare utilization and health events⌘ relative to Low 
Multimorbidity class, n=604 ALIVE participants from 2014-2018 














































































































⌘ Controlling for baseline age, sex, race, income, disability, insurance, same provider>90% of visits, and substance 
use 
 
§ Medication for Opioid Use Disorder (MOUD) includes prescription of buprenorphine, naltrexone, or methadone in the 
last 6 months of the participant’s last visit in 2018 
 
¥ Cardiovascular events include self-report myocardial infraction, heart failure, heart disease, or stroke between 2014-
2018 
 
* Infectious events include self-report sepsis, pneumonia, endocarditis, or skin infection between 2014-2018 
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Background: People who inject drugs (PWID) have increased risk of morbidity and mortality 
related to their substance use and an increased burden of multimorbid chronic diseases. It is 
necessary thorough the experiences of this population to understand how management of 
multimorbid diseases, decisions to initiate treatment for substance use, and structural factors 
coalesce into healthcare engagement. The purpose of this study is to explore how this population 
engages in healthcare across three distinct classes of multimorbid burden.  
Methods: This study is the qualitative aim 2 of an explanatory sequential mixed methods study. 
Quantitative findings from aim 1 identified three distinct classes of multimorbidity. Purposive 
sampling was conducted from each multimorbid class for semi-structured interviews to 
understand implications of engagement in care within and between classes. Qualitative 
descriptive method was applied for thematic analysis using the Behavioral Model for Vulnerable 
Populations as a conceptual framework.  
Results: Participants in all three multimorbidity classes reported general adequacy of their 
current health insurance plans with some gaps in coverage described. Degree of multimorbidity 
impacted how individuals conceptualized being healthy with respect to their healthcare needs 
and whether perceived and actual needs aligned. Participants in each class listed different 
motivations and sources of information for managing their chronic diseases, with two classes 
listing the need to manage their mental health or active substance use before they could manage 
other multimorbid diseases.  Finally, while specific advice given by participants for cessation of 
substance use differed by each class, participants across all three consistently listed that 
providers could not provide services for cessation to patients, “until they were ready.”  
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Discussion: Participants in this study highlighted multiple avenues for healthcare engagement. 
Policy considerations include low barrier access to public insurance, legislation that provides 
funding for clinics to provide wrap-around services to individuals with substance use disorder 
and removing MOUD prescription barriers. This study affirms the importance of healthcare 





People who inject drugs (PWID) have increased risk of morbidity and mortality related to 
their substance use, including increased risk of overdose, Hepatitis C, and HIV (Bruneau, Roy, 
Arruda, Zang, & Jutras-Aswad, 2012; Martins, Sampson, Cerda, & Galea, 2015; Puzhko et al., 
2017; Zibbell et al., 2018). Additionally, PWID continue to age and have an increased burden of 
multimorbid chronic diseases. The AIDS Linked Intravenous Experience (ALIVE) study, a 
Baltimore based longitudinal cohort of current and former PWID, previously identified high 
prevalence of multimorbid chronic conditions (Salter, Lau, Go, Mehta, & Kirk, 2011). 
Engagement in healthcare is essential for people who inject drugs (PWID) to receive harm 
reduction, medication for opioid use disorder (MOUD), and to address multimorbid chronic 
conditions to prevent excess morbidity and mortality (National Prevention Council, 2011; Office 
of National Drug Policy, 2010). 
According to the Center for Advancing Health, engagement in healthcare is defined as, 
“actions individuals must take to obtain the greatest benefit from the healthcare services 
available to them” (Gruman et al., 2010). Data from Hepatitis C and HIV studies indicate that 
PWID engage in care at low rates, are less likely to access HCV and HIV testing, are often seen 
in later stages of disease, and face social and structural barriers (Artenie et al., 2015; Larney et 
al., 2017; Okeke, Ostermann, & Thielman, 2015; Oramasionwu, Moore, & Toliver, 2014; 
Thompson, Mugavero, Amico, & Cargill, 2018). Among PWID, younger age, incarceration, 
homelessness, lack of health insurance, poor provider continuity, and active substance use are 
predictors of poor engagement (Hartzler et al., 2018; Westergaard, Hess, Astemborski, Mehta, & 
Kirk, 2013; Westergaard, Kirk, Richesson, Galai, & Mehta, 2011). Understanding the complex 
nature of healthcare engagement for PWID is essential as prior work has shown engagement to 
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be limited, and this lower engagement is associated with poor health outcomes (Gryczynski, 
Mitchell, Peterson, Gonzales, & Schwartz, 2012; Madras et al., 2010) 
PWID have poor prognosis related to substance use treatment and recovery as well as 
control of their multimorbid chronic diseases (Go et al., 2014; Joseph et al., 2016; Lazarus et al., 
2016). This highlights the need for further research to examine engagement in healthcare for 
both substance use and other multimorbid chronic disease treatment and management.  
Addressing substance use as another multimorbid chronic disease facilitates delivery of high 
quality care to this vulnerable population. Given the lack of evidence regarding holistic 
healthcare engagement for PWID, it is necessary thorough the experiences of this population to 
understand how management of multimorbid diseases, decisions to initiate treatment for 
substance use, and structural factors coalesce into healthcare engagement.  
Figure 1 describes the Behavioral Model for Vulnerable Populations (BMVP) is to 
examine healthcare engagement. From the model, Predisposing, Enabling, Need, and Health 
Behavior factors influence healthcare utilization and engagement (Andersen, 1968; Gelberg, 
Andersen, & Leake, 2000). Predisposing factors are individual characteristics such as age, 
gender, and relationship status, sexual orientation, and substance use (Gelberg et al., 2000). 
Enabling characteristics are organizational and financing factors such as health insurance status, 
health service resources, and region of residence (Gelberg et al., 2000). Need characteristics refer 
to those that are both perceived by an individual and those evaluated by healthcare providers 
(Gelberg et al., 2000). Health Behaviors are actions taken by individuals for management of their 
multimorbid diseases and substance use (Gelberg et al., 2000). This framework is useful to study 
healthcare engagement among people who inject drugs, because it provides a framework to 
understand characteristics associated with engagement in care salient to PWID.  
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The following is the second aim of an explanatory sequential mixed methods study 
nested within the ongoing ALIVE cohort. The purpose of this study is to explore how this 
population engages in healthcare across three distinct classes of multimorbidity. This study adds 
information for care engagement for this older population of PWID and the role healthcare 
environments play in their drug use or recovery. Qualitative findings from the qualitative aim are 
the focus of this report. 
Methods  
Parent Study  
The AIDS Linked Intravenous Experience (ALIVE) study is a Baltimore, MD based 
community cohort of current and former people who inject drugs (PWID). Study methods have 
been published elsewhere (Vlahov et al., 1991). In brief, eligible participants were first recruited 
when the cohort was established in 1988 or during one of the subsequent recruitment waves 
during 1994-1995, 1999, 2005-2008, and 2015-2018. Eligibility criteria included being 18 years 
or older and injection drug use in the previous 6 months. Participants underwent biannual visits 
with an interview, clinical examination, and biospecimen collection. All participants provided 
written informed consent prior to participation in ALIVE. 
Aim 1 and Sampling: 
The present qualitative study is part of a sequential mixed methods study with the 
following research question: What are the healthcare needs of an aging population who inject 
drugs and how do they engage in their healthcare? Quantitative analysis from aim 1 of this study 
identified three unique classes of multimorbidity present within this population, based on the 
degree of disease probabilities present in each class. Low Multimorbidity (n=163, 27%) was the 
smallest class, with low probabilities of all eight diseases compared to the other two classes, 
  
 89 
though there was still a high probability of hypertension (67%). The Multimorbidity class 
(n=190, 31%) had the highest probabilities on 6 of the 8 diseases studied. Finally, the 
Multimorbidity with Psychiatric Comorbidity class (n=251, 42%) had high probabilities of all 
diseases studied and the highest probabilities for the mental health disease indicators 
(Bipolar/Schizophrenia and Anxiety/Depression). A maximum variation, purposive sample for 
qualitative interviews was conducted with representation from each of the three multimorbidity 
classes to allow us to explore similarities, differences, and process of healthcare experience and 
engagement within and between classes (Palinkas et al., 2015; Sandelowski, 2000) 
Study procedures: 
 24 semi-structured qualitative interviews with ALIVE participants were conducted 
during their regularly scheduled study visit occurring between June 2019-September 2019. 
Interviews lasted between 20 to 60 minutes. Participants were eligible for inclusion if their data 
were included in the quantitative arm and were sampled for representation within each of the 3 
identified classes until saturation occurred. Saturation was reached at interview 20, with an 
additional 4 interviews conducted for better distribution of participants in each class. In-depth 
interviews were conducted to explore experiences and process with healthcare utilization and 
engagement including those previously described within the Behavioral Model for Vulnerable 
Populations, findings from quantitative analysis. At the end of the interview participants received 
$20 for their time. All participants provided oral informed consent and all agreed to audio 
recording of the interview. The Johns Hopkins Bloomberg School of Public Health Institutional 
Review Board approved study procedures. The consolidated criteria for reporting qualitative 
research (COREQ) was utilized to maximize quality and trustworthiness (Tong, Sainsbury, & 
Craig, 2007).  
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Qualitative Data Analysis: 
 Interviews were audio recorded and transcribed by an IRB approved transcription service, 
following data storage and handling procedures prescribed by the IRB. Using the BMVP as a 
guiding framework, a qualitative description methodology was applied, focusing on participant’s 
perspectives with the phenomena of interest, healthcare engagement, (Bradshaw, Atkinson, & 
Doody, 2017).  OH developed the initial codebook with a priori codes based on the BMVP 
(Gelberg et al., 2000; Miles & Huberman, 1994). The study team then met to listen to multiple 
interviews, revise a priori codes and conduct in vivo coding (Miles & Huberman, 1994). The 
domains utilized from the BMVP model for our study were: Enabling, Needs, and Health 
Behavior characteristics. Enabling characteristics included health insurance, income, and 
nonfinancial enablers including regular source of care, receipt of public benefits, and competing 
needs. Need characteristics encompassed a combination of participant perceived health needs 
and diagnosed diseases (actual need). Finally, Health Behaviors, actions taken and resources 
utilized by participants to control their chronic multimorbid diseases, were separately coded for 
those applying to chronic diseases (including mental health disorders) and those related to 
substance use.  
  Coding was conducted in Atlas.ti version 8.4. The research team independently coded 
multiple transcripts. Inconsistencies in coding were reviewed with revisions to the codebook 
until sufficient inter-coder agreement was reached (Krippendorf’s alpha=0.78). Thematic 
analysis was conducted as codes were examined within each class, exploring and expanding 
major domain from the BVMP Model. Themes were considered as related responses with similar 
meaning and novel responses that were associated with the interview question (Denzin & 
Lincoln, 2011; Ryan & Bernard, 2003). Themes were also related participant responses that 
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provided novel understanding of their engagement in healthcare (Miles & Huberman, 1994; 
Saldana, 2009). Data presented in this study are themes related to healthcare utilization and 
engagement for an older cohort of current and former PWID, stratified by their membership 
within their multimorbidity class. Themes not directly related to the research question of this 
study, including those regarding safe injection/safe consumption spaces, are not included.  
Results 
 A total of 24 participants were recruited across all three multimorbidity classes: Low 
Multimorbidity (n=9), Multimorbidity (n=5), and Multimorbidity with Psychiatric Comorbidity 
(n=10). Table 1 presents a list of participant characteristics, with no significant differences noted 
between classes. The majority of the study population was Black (83%) and male (62.5%). The 
median age of participants was 58 years old (range: 35-74) with similar median and range in all 
three multimorbidity classes. Slightly more than half the participants reported high school 
education (52%). A majority of participants reported an bi-annual income of less than $5,000; 
67% reported receipt of disability services (Supplemental Security Income or Social Security 
Disability Income). All but one participant reported health insurance. Finally, 9 participants 
(37.5%) reported injection drug use in the previous six months.  
Thematic Findings 
  Thematic finding are presented within the following domains from the BMVP: Enabling, 
Need, and Health Behavior (health behavior is separated by those that apply to chronic disease 
and those related to substance use). Themes that emerged within each domain below include 
both a priori from the BMVP and those that emerged in vivo from the open-ended questions. The 




 Three themes are described from the data: Financial coverage, Patient-provider 
relationship, and Service integration. Financial coverage and Patient-provider relationship were 
conceptualized a priori as salient to the enabling domain from the BMVP. The Service 
integration theme emerged in vivo and had the most relevance to this domain. Table 2 presents 
Enabling findings across classes of multimorbidity. 
 Financial coverage. Across all three classes no financial barriers to care reported. All 
participants reported health insurance coverage or an ability to pay for their care, including 
prescription coverage. In the Multimorbidity with Psychiatric Comorbidity class, the majority 
described a clinic service that reduced out of pocket costs for healthcare or linked them to health 
insurance. One participant described the clinic services, “I've got an insurance card. I've got a 
counselor so…if something's wrong or anything, just let her know and she'll take care of it” 
(ID024). While not specifically described as a barrier to overall healthcare engagement, at least 
one participant in each class reported gaps in coverage for dental and vision care, which could 
not be addressed with their current insurance plans.  
Patient-provider relationship. Participants across the three classes described being 
satisfied and engaged in their healthcare when they viewed the relationship with their provider 
positively, including communication and continuity. Additionally, a majority of participants in 
the Low Multimorbidity class described positive experiences with provider. These positive 
experiences were often linked to an aspect of their care (i.e. the PCP also prescribed medication 
for opioid use disorder [MOUD] or treatment for HCV treatment), which facilitated their 
engagement. However, a third of the participants, reported some perceptions of stigma from 
providers compounded by competing financial priorities that influenced their decision to not 
engage in their healthcare and described a preference for ED or urgent care. Two additional 
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participant listed negative experiences of stigma, but their solution was to change healthcare 
providers. Participants in the Multimorbidity with Psychiatric Comorbidity class described 
returning for appointments and engagement with providers, for which, they described a 
‘friendship-like’ quality to the relationship. Many who described positive patient-provider 
relationships also had long-term continuity with a provider with whom they build a strong 
rapport and their communication was established: 
“But to me it's more like a friend because she probes until she can find out what's going on with 
you and try to help you because people have crisis and just by looking you can't tell what's going 
on with a person, sometimes you have to dig a little deeper” ID014 
 Service integration.  Participants described the benefits of integrated care services on care 
engagement, but at differing frequency and quality in each class. Only three participants in the 
Low Multimorbidity class reported integrated care services. Two were pleased that their PCP also 
prescribed their MOUD; another was satisfied with the ability to see a mental health provider 
and therapist at the same location as their medical care.  All participants in the Multimorbidity 
class reported engagement with a primary care provider only, or having to go to multiple 
locations due to specialty care referrals. One patient, in particular, experienced fragmented care 
and challenging pain management in a situation where both their primary and specialty care 
providers no longer wanted to prescribe opioids for chronic pain management, a service which 
was previously integrated in their primary care management: 
“I've been taking pain medicine for the last 20 years….they have been treating me for chronic 
pain. And for the last year and a half, ever since the fentanyl breakout in the city, they have gotten 
real fearful with treating people that have chronic pain with narcotics. And they no longer does 
that. And I was referred to pain management, and the majority of the pain management clinics that 
I had went to wanted to treat my pain with the [suboxone]. Those are medicines that I had never 
heard of before, never tried them before. So I opted not to take it. So because I opted not to take it, 
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they wouldn't treat me. So I'm in the process of trying to find someone to treat my pain 
management.” ID005 
Participants in the Multimorbidity with Psychiatric Comorbidity class described overall 
satisfaction when mental health and primary care were integrated in the same facility or managed 
by the same provider. Additionally, being at the same facility was perceived positively by those 
accessing MOUD. Communication between providers in an integrated center was particularly 
important. As one participant complained: “When I come out of there [ED] after 3 days, the 
program don't know nothing about it…doctor’s don’t talk to each other, they’re both prescribing 
medications, they will not talk to each other about the patient” ID016.  
Need  
 Two themes are described from the Need domain: Health construct and Alignment of 
needs. While neither theme appears within the BMVP, they are derived of the definition of Need 
in the BMVP. Perceived health needs are those described but participant subjectively while 
actual needs are underlying disease states (i.e. diagnosed by a healthcare provider). Health 
construct was conceptualized a priori to describe participant’s perceived need. The Alignment of 
needs theme emerged in vivo and allows understanding of the relationship between perceived 
and actual need as they relate to engagement in care. Table 3 presents Need findings across the 
three classes. 
 Health construct. Participants from the three classes described their conceptualizations of 
health and what it meant for their healthcare needs. Distinct patterns emerged from each class. 
Almost all of the participants in the Low Multimorbidity class described their health construct in 
tangible terms with a focus on lifestyle modifications and a focus on preventative health 
(exercise, eating well, sleep, not smoking). In stark contrast, almost all individuals in the 
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Multimorbidity class described their healthy construct in more extreme terms of living versus 
dying:  
“S2: It means staying alive or dying. You got two choices. You either live or you die. That's the 
only choices you got. The rest is just in-between. 
S1: Okay. Is there an in-between in staying alive? Is there an optimal way to live or a not so 
optimal? 
S2: You're here to live or to die. The rest, you are on your own. So you got to figure out which 
way you going here. You want to live, you go that way. You don't want to live, I guess you going 
that way” ID 007 
Nearly all participants experiencing Multimorbidity with Psychiatric Comorbidity described 
more tangible health constructs, listing specific behaviors of disease management. This was 
particularly true concerning mental health discussions: “Being healthy means being conscious, 
updated, and mindful of the things that's going on with me through the things that I do to me; and 
seeking help in an ample amount of time” ID016. A few participants in this class described their 
health as being rooted in a desire to live informed by their past traumas, with one participant 
describing being healthy as, “…taking care of yourself, being in a safe environment, taking care 
of your body, your mind, your soul, your whole physical being…my psychiatrist, dealing with 
my depression, my family, support, and I have financial assistance, a stable place to live, things 
like that.” ID019.  
 Alignment of Needs. Engagement in and satisfaction with care was higher for those 
participants who had an alignment of their self-perceived and actual needs (those diagnosed by 
the provider). This theme was unique to the Multimorbidity with Psychiatric Comorbidity class 
alone, as participants who were satisfied with their healthcare described their perceived health 
needs met by providers, as well as providers working with them to better align perceived and 
actual needs with resources and education:  
  
 96 
“When I first came there…told me that they didn't know what to do with me because I was so 
angry. I was a very angry person…. And I was trying to-- they were trying to put me on the right 
medication that would stabilize me because I was just everywhere at that time. And it took them 
about five years to get me on the right medication…the people there, they were hands on. They 
seen that I needed a little extra help. And they just love me. I mean, I have a great personality. 
Deep down inside, I do have a temper. But I help people out. They help me out.” ID021 
Health Behaviors- Chronic Disease 
 Two themes are described from this domain: Advice and resources, and Social networks. 
Advice and resources was conceptualized a priori as a theme relating to the health behaviors 
participants found salient to their care engagement. Social networks as it related to participant’s 
health behaviors for chronic disease management emerged a theme within this domain. Table 4 
presents Chronic Disease Health Behavior findings. 
 Advice and Resources- Chronic Disease. This theme captured the advice given by 
participants to healthcare providers or resources utilized by participants from their care team that 
allowed them to better control their chronic diseases and engage in care. Participants in the Low 
Multimorbidity class discussed substance use cessation as a necessary step before chronic disease 
management. Many also listed the benefit of MOUD and other substance use services (therapy, 
group counseling, etc.) as important resources necessary before they could engage in care. In 
contrast, all but one of the Multimorbidity participants listed lifestyle modifications as the largest 
source of chronic disease management from their healthcare team. Nearly all Multimorbidity 
with Psychiatric Comorbidity participant described their care team as central to keeping them 
engaged in care by being a source for services, information, care coordination, and 
encouragement. However, they presented this could only occur when the participant was ready to 
engage in their care: 
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“They keep me going anything-- anything I have. I be asking questions... And they had helped me 
for years but I've been with them for a long time… Well, one thing is up to the person. If they're 
willing to keep their health or want to. And understand what they're going to do with their life. 
There's people out there, man, that's healthy and everything and some don't care” ID011 
 Social Networks.  Participants in the Low Multimorbidity and Multimorbidity with 
Psychiatric Comorbidity classes described how their social networks acted as barriers and 
facilitators to chronic disease management.  Participants in the Low Multimorbidity class 
reviewed how some aspects of social networks and environment acted as facilitators to disease 
management while others could act as barriers to long term SUD recovery and compete with 
their health needs: 
“Just change of environment really, that's the basics right there. And my family helps out a lot. We 
do a lot of things together, talk, and social…For me it was environment because I'm from the 
streets pretty much and just to maintain what I have now I have to stay away from that atmosphere 
and I try. I still have some friends that are-- but, like I said, I try to for the most part stay away 
from them.” ID023 
Multimorbidity with Psychiatric Comorbidity participants distinctly described their social 
networks as a source of knowledge and experience for managing chronic diseases as well as a 
source of strength through their care journey, exemplified by, “That's why I talk to certain 
people, what they going through, and I tell them what I'm going through… we'll be sharing 
information for us or what to do, or what type of help to get to help each other and whatnot” 
ID002.  
Health Behaviors- Substance Use 
 Two themes are described from this domain: Advice and resources, and Sustained 
recovery. Sustained recovery was an a priori theme as it provided insight behaviors for 
management of substance use disorder. Advice and resources was also conceptualized a priori as 
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a theme relating to what participants found salient to their care engagement with respect to their 
current or recovery from substance use. Table 5 presents Substance Use Health Behavior 
findings in the three multimorbidity classes.  
 Sustained Recovery. Participants across the three classes discussed differential patterns of 
treatment sought for sustained recovery from substance use. The Multimorbidity class was 
distinct as participants discussed quitting substance use without the use of MOUD. Some even 
expressed some negative impressions regarding MOUD use: 
I know people that's been on the methadone program for 30 years. 30 years! They need to have 
some kind of cutoff. …I didn't take no methadone. I didn't go in no detox. I just got tired of being 
tired. I just told myself, "Okay. You'll be sick for a few days. It's better for you to be sick for two, 
or three, or four days than you having to go [out wait here?] for months and years and years and 
wondering, do whatever to try to get the drug."  ID005 
In contrast, half of the Low Multimorbidity class and nearly all with Multimorbidity with 
Psychiatric Comorbidity described either MOUD or treatment for mental health comorbidities as 
a means for stability that allowed them to reduce their substance use:  
When I first came there… they were trying to put me on the right medication that would stabilize 
me because I was just everywhere at that time. And it took them about five years to get me on the 
right medication. The PRP program, and the people there, they were hands on. They seen that I 
needed a little extra help. And they just love me. I mean, I have a great personality. Deep down 
inside, I do have a temper. But I help people out. They help me out. Do class work together.” 
ID021 
 Advice and Resources- Substance Use. This theme concerned advice to healthcare 
providers or resources utilized by participants that allowed them to better control their substance 
use and engage in care. The vast majority of participants across the three classes stated that 
providers could not help their patients with substance use cessation, “until they were ready.” The 
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participants, however, emphasized the importance for providers to remain an open source of 
care, even for patients with active use or relapse. All participants, but particularly those in the 
Low Multimorbidity and Multimorbidity with Psychiatric Comorbidity classes, advised care 
teams to meet participants where they are in their recovery, emphasizing that providers should 
provide a positive and accepting presence at care opportunities: 
“Just talk to them. And if you got an individual that has taken to you, listening to you, keep going 
to that person. That person might finally change like I did… Because everybody has a soul. 
Everybody has a heart. And like I said, show them that you have a heart, put down, don't be scared 
to help them. Don't be scared to stand to talk to them. Don't be scared to drink a cup of coffee with 
them or something.” ID006 
“Listen to them. Just listen. And just encourage them. They can get better. Because a lot of people 
don't do that. They just, "Well, you're using, and you want to go kill yourself, just go kill 
yourself." But if they got somebody that's positive in their corner, it's a big difference.” ID025 
One participant advised providers to learn as much as possible about their patient’s substance use 
and personal triggers as a mitigating strategy and to offer counseling for sustained recovery. 
Additionally, participants in the Multimorbidity class most consistently advised the use of 
incentives as a means to encourage recovery. One participant suggested, “Like if they do come 
meet all the appointments, they give them like $25. If they meet all they appointments. And the 
second is for people that don't come, they give them like $125 so they can come” ID020.  
Discussion 
 
 This study explored healthcare needs and engagement for an aging population of current 
and former people who inject drugs from three distinct classes of multimorbidity.  Our findings 
suggest that the healthcare needs and engagement in care are unique within each multimorbid 
class, with some areas of overlap. Multiple themes emerged from each domain, some of which 
were novel or otherwise unexpected based on what was already known in this area. First, the lack 
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of financial barriers described by participants with respect to healthcare costs and insurance 
stood out for this mostly low-income and vulnerable population. The alignment of participant’s 
healthcare needs emerged as a theme with particular relevance to overall engagement in care and 
highlighted one of the limitations of using the BMVP as a conceptual framework. Social 
networks emerged from participants describing their ability to manage their chronic diseases due 
to their social network, discussed within the context of the health behavior theme rather than one 
in the enabling domain. Finally, within the a priori theme of Advice and resources for the Health 
behaviors-Substance use domain, each multimorbidity class provided important 
contextualization for how they experience healthcare systems, suggesting implications for future 
research and clinic practice given their underlying comorbidities. Specific implications for each 
theme are described below. Consistent with our a priori themes, participants in each class listed 
different motivations and sources of information for managing their chronic diseases, with two 
classes listing the need to manage their mental health or active substance use before they could 
manage other multimorbid diseases.  While specific advice given by participants for cessation of 
substance use differed by each class, participants across all three consistently listed that 
providers could not provide services for cessation to patients, “until they were ready.” 
 From the enabling domain, access to and coverage by health insurance was listed as a 
facilitator across all three classes. Many studies have confirmed this finding, demonstrating a 
positive association between health insurance and health engagement (Barocas et al., 2014; 
Hoots, Finlayson, Broz, & Paz-Bailey, 2017; Knowlton et al., 2010; Riley et al., 2002; Wilkinson 
et al., 2007). This evidence could indicate that provisions that expand healthcare services, 
particularly the ACA that expanded Medicaid in states like Maryland, where this study was 
conducted, are particularly important to maintaining security with respect to health insurance. 
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Participants in the three classes did list gaps in dental and vision coverage, areas currently not 
covered by public insurance but could be targeted for future legislation that expands healthcare.  
Participants listed their patient-provider relationship as an important factor in their 
healthcare engagement, consistent with existing literature (Barocas et al., 2014; Biello et al., 
2018; Knowlton et al., 2010; Skeer, Ladin, Wilkins, Landy, & Stopka, 2018). Having a 
friendship like quality to their relationship, potentially indicative of long-term care continuity 
with a provider, was particularly important to the multimorbidity class with the highest 
probability of mental health disorders. Participants in the Low Multimorbidity class reported a 
positive patient-provider relationship when care was integrated with one provider. The 
participants in Multimorbidity with Psychiatric Comorbidity echoed a similar sentiment, with 
particular focus on the desirability of accessing their primary care and mental health services in 
the same location. Co-location of services for this population has received increased national 
attention from policy makers, with a report from the Surgeon General listing the growing 
impetus from integrated care services for this population as a key area for health centers to 
increase capacity (US Department of Health and Human Services [DHHS], 2016). 
 Participant’s experiences from these interviews provided novel insight into their 
conceptualization of health as a construct with respect to their healthcare needs, the degree to 
which these perceived needs aligned with their actual needs, and the context of this for 
engagement in care. The findings across the three classes indicated that those with closer 
alignment of their perceived and actual needs had greater engagement in care. The health 
constructs were also reflective of the degree of multimorbidity present in the class. The Low 
Multimorbidity class listed their health constructs and needs with respect to preventative health 
behaviors (i.e. quitting smoking, losing weight, etc.) while the Multimorbidity with Psychiatric 
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Comorbidity class described specific provisions in their health construct and needs with respect 
to mental health care. Based on participant descriptions, the Health Belief Model may offer 
better constructs to understand these findings. Participants in the Low Multimorbidity class had 
lower level of perceived susceptibility and severity of health problems in contrast to those in the 
Multimorbidity with Psychiatric Comorbidity class. This later class also had high perceived 
susceptibility and severity of disease, particularly with respect to their mental health, while also 
influenced by perceived benefits of seeing their providers and taking actions for their health 
management (Becker, 1974; Champion & Skinner, 2008). Future studies with this population 
may benefit from an adaptation of the BMVP to include provisions from the health belief model 
to better understand specific constructs in the Needs domain, such factors of perceived 
susceptibility and severity of disease, perceived benefits of care, and health motivation (Becker, 
1974; Champion & Skinner, 2008).   
 Health behaviors to manage chronic diseases varied across classes and were likely a 
function of the multimorbidity class. Participants in their Multimorbidity with Psychiatric 
Comorbidity class in particular listed their care team and wrap around services as useful for their 
healthcare engagement, particularly for their mental health. These participants later also listed 
the need to stabilize their mental health as a provision for cessation from substance use and 
injection., Multiple studies have shown that substance use and mental health disorders are highly 
correlated (Kelly & Daley, 2013; Klinkenberg & Sacks, 2004; Ross & Peselow, 2012). While no 
study could be located to confirm our findings of a participant descriptions of stabilizing mental 
health as a means for substance use cessation, some studies identified an unmet treatment need 
for individuals with triple diagnosis of substance use disorder, mental health disorder, and 
chronic disease. There is also some evidence demonstrating an improvement of chronic disease 
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management following treatment for mental health disorder (Klinkenberg & Sacks, 2004; Tegger 
et al., 2008). Wrap-around services provide linkage to services including disability, housing, and 
social worker support. (Kay & Westfall, 2020). These services, however, are not often available 
at all clinic facilities and are often limited when available. The Comprehensive Addiction 
Resources Emergency (CARE) Act provides funding to health centers and systems for hiring 
clinicians and ancillary healthcare workers to provide these wrap-around services and improve 
engagement in care, particularly for the vulnerable subset of individuals with co-occurring 
mental health disorders (H.R.2569, 2019). Legislation of this nature expands much needed 
services that are often underfunded but were highlighted by study participants as necessary 
resources utilized for healthcare engagement.  
 Participants across the three classes listed their social networks as both barriers and 
facilitators to healthcare engagement. In particular, participants in all classes generally listed that 
their social networks could be a source of information to control their chronic disease but could 
also pose barriers to substance use recovery and management of their mental health. Previous 
studies have confirmed the role of social networks as both barriers and facilitators to care 
management (Biello et al., 2018; Broadhead et al., 2002; Latkin et al., 2008). Clinicians should 
view individual’s social networks as a key area for assessment and intervention, leveraging 
positive interactions as a means for ongoing engagement while counseling their patients to be 
mindful and providing support to avoid social networks that are deleterious to their health and 
care outcomes. Additionally, peer groups and counseling could be a means to achieve the 
benefits of healthcare engagement while also providing insights and resources to more 
effectively manage social networks that present barriers to long term recovery and care 
(Broadhead et al., 2002; Latkin et al., 2008).  
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 The use of medication for opioid use disorder varied across class, with participants in the 
Multimorbidity class listing non-medication strategies for recovery and even expressing some 
stigma against those who required medications. While not directly reported by participants, their 
language mirrored some language from 12-step programs, where there has been a persistent 
cultural stigma against those who utilize MOUD.  Despite this, there is robust evidence of the 
benefits of MOUD, confirmed by participants in the Low Multimorbidity and Multimorbidity 
with Psychiatric Comorbidity class (Islam et al., 2013; Mehta et al., 2015; Miller et al., 2018; 
Morozova, Dvoriak, Pykalo, & Altice, 2017; Parmenter et al., 2013; Wang et al., 2013). Primary 
and integrated care facilities should provide MOUD for individuals with current or recovering 
substance use (DHHS, 2016). Additionally, there is evidence that peer based support groups, 
similar to 12 step programs, can play a role in long term recovery when they provide a holistic 
and non-stigmatized environment for participants (Krawczyk, Negron, Nieto, Agus, & 
Fingerhood, 2018). Finally, lack of providers with licenses to prescribe MOUD or limitations to 
the number of patients for whom they can prescribe has been shown to be a barrier to MOUD 
access for this population (Marino et al., 2019). Given participant’s clear indication of MOUD as 
a provision for healthcare engagement, future legislation should remove barriers that healthcare 
providers face and allow for a seamless transition into integrated care.  
 There are limitations to consider. The study population is from an aging cohort in an 
urban setting with demographics that are not representative of the general substance using 
population. Additionally, the study presented here is the qualitative aim from a larger 
explanatory sequential mixed methods study. Participants were only eligible if they met 
inclusion criteria for the quantitative aim, limiting to participants surviving for data collection 
between 2014-2018 and with a high number of study visit. Given time constraints and difficulty 
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with recruitment, member checking of the analysis presented here was not done. Additionally, 
while there was similar distribution for two classes, the number of participants in the 
Multimorbidity class was low (n=5). However, there were 24 interviews conducted in total, with 
thematic analysis consistent across all three classes for many themes. Finally, participants were 
only able to be interviewed once, with some qualitative methodologists suggesting multiple 
interviews to improve trustworthiness of data (Murray et al., 2009; Polkinghorne, 2005). Overall, 
our participants were able to relate experiences with healthcare, sampling from classes of 
multimorbidity, allowing us to obtain a holistic understanding of how this aging population 
engages in their healthcare for their complex needs.  
 Future studies with this population should be conducted with an adapted framework of 
the BMVP with the Health Belief Model to better understand the healthcare needs of individuals 
with SUD. Better understanding of participant’s perceptions for optimal healthcare engagement 
can provide additional avenues for interventions and leverage strengths for sustained healthcare. 
Participants in this study highlighted multiple avenues for healthcare engagement, including 
positive patient-provider relationship, sustained health insurance, alignment of their healthcare 
needs with those designated by healthcare providers, and receipt of integrated care that can 
address pressing health needs. Policy considerations include the continued provision of low 
barrier access to public available insurance, passage of legislation that provides funding for 
clinics to provide wrap-around services to individuals with substance use disorder and removing 
MOUD prescription barriers. Finally, this study affirms the importance of healthcare integration 
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Table 4.1 Study sample baseline, 24 ALIVE participants from 3 Multimorbidity classes 















(mean, std. dev) 
57 (4.4) 58 (6.1) 58 (10.4) 
Female sex 2 (22%) 4 (80%) 3 (30%) 
Race 8 (89%) 4 (80%) 8 (80%) 
Enabling 
Insurance 7 (88%) 5 (100%) 10 (100%) 
Income 4 (44%) 3 (60%) 6 (60%) 
Disability 5 (56%) 3 (60%) 8 (80%) 
Same provider  
last 2 years 
5 (56%) 2 (40%) 6 (60%) 
Health Behaviors (last 6 months) 
Any drug use*  4 (44%) 1 (20%) 6 (60%) 
Injection drug  
use only 
3 (33%) 0 (0%) 6 (60%) 
Alcohol 3 (33%) 2 (40%) 5 (50%) 
Cigarettes 7 (78%) 4 (80%) 7 (70%) 
Healthcare Utilization (last 6 months) 
Emergency Room Visit  1 (11%) 2 (40%) 2 (20%) 
Outpatient Clinic Visit 4 (44%) 4 (80%) 8 (80%) 
Medication for  
Opioid Use Disorder  
5 (56%) 2 (40%) 6 (60%) 
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Table 4.2 Thematic analysis from the Enabling domain across three Multimorbidity classes 
Domain: 
ENABLING 
Multimorbidity Class  
Subthemes Class 1: Low Multimorbidity (n=9) 
Class 2: Multimorbidity 
(n=5) 




Financial Across all three classes no financial barriers to care reported. All participants reported health insurance coverage or an ability to pay for their care, including prescription coverage. 
“I've got an insurance 
card. I've got a 
counselor so…if 
something's wrong or 
anything, just let her 
know and she'll take 





Participants across the three classes described being satisfied and engaged in their healthcare when 
they viewed the relationship with their provider positively, including communication and continuity. 
“But to me it's more 
like a friend because 
she probes until she can 
find out what's going 
on with you and try to 
help you because 
people have crises and 
just by looking you 
can't tell what's going 
on with a person, 
sometimes you have to 
dig a little deeper” 
(ID014, Class 2) 
Service 
integration  
A minority (n=3) of Class 1 
participants reported integrated care 
services for MOUD or mental 
healthcare  
All Class 2 participants 
reported engagement with a 
primary care provider or 
having to go to multiple 
locations due referrals 
Class 3 participants 
described overall 
satisfaction when mental 
health and primary care 
were integrated in the same 






Table 4.3 Thematic analysis from the Enabling domain across three Multimorbidity classes 
Domain: 
NEED 
Multimorbidity Class  
Subthemes 
Class 1: Low 
Multimorbidity 
(n=9) 
Class 2: Multimorbidity 
(n=5) 





Almost all of the Class 
1 participants described 
their health construct in 
tangible terms with a 
focus on lifestyle 
modifications and a 
focus on preventative 
health (exercise, eating 
well, sleep, not 
smoking) 
Almost all Class 2 
individuals described 
their healthy construct 
in more extreme terms 
of living or dying.  
Nearly all Class 3 
participants described 
more tangible health 
constructs, listing 
specific behaviors of 
disease management. 
This was particularly 
true concerning mental 
health discussions. 
 
“It means staying alive or dying. You got two choices. 
You either live or you die. That's the only choices you 
got. The rest is just in-between…You're here to live or 
to die. The rest, you are on your own. So you got to 
figure out which way you going here. You want to live, 
you go that way. You don't want to live, I guess you 
going that way” ID 007, Class 2 
 
“Being healthy means being conscious, updated, and 
mindful of the things that's going on with me through 
the things that I do to me; and seeking help in an ample 
amount of time” ID016, Class 3  
Alignment of Needs 
  Class 3 participants 
who were satisfied with 
their healthcare 
described their 
perceived health needs 
met by providers, as 
well as providers 
working with them to 
better align perceived 
and actual needs with 
resources and education 
“When I first came there…told me that they didn't know 
what to do with me because I was so angry. I was a very 
angry person…. And I was trying to-- they were trying 
to put me on the right medication that would stabilize 
me because I was just everywhere at that time. And it 
took them about five years to get me on the right 
medication…the people there, they were hands on. They 
seen that I needed a little extra help. And they just love 
me. I mean, I have a great personality. Deep down 
inside, I do have a temper. But I help people out. They 
help me out.” ID021, Class 3 
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Multimorbidity Class  
Subthemes 
Class 1: Low 
Multimorbidity 
(n=9) 
Class 2: Multimorbidity 
(n=5) 




Advice and  
Resources 
Class 1 discussed 
substance use cessation 
as a necessary step 
before chronic disease 
management. Many 
listed MOUD and other 
substance use services 
(therapy, group 
counseling, etc.) as 
important resources.  
All but one of Class 2 
participants listed 
lifestyle modifications 
as the largest source of 
chronic disease 
management from their 
healthcare team 
Participants described 
their care team as 
central to keeping them 
engaged in care by 
being a source for 
services, information, 
care coordination, and 
encouragement 
“They keep me going anything-- anything I have. I be 
asking questions... And they had helped me for years but 
I've been with them for a long time… Well, one thing is 
up to the person. If they're willing to keep their health or 
want to. And understand what they're going to do with 
their life. There's people out there, man, that's healthy 
and everything and some don't care”  
ID011, Class 3 
 
Social Networks 
Participants in Class 1 
reviewed how some 
aspects of social 
networks and 
environment acted as 
facilitators to disease 
management while 
others could act as 
barriers to long term 
SUD recovery and 
compete with their 
health needs 
 Participants in Class 3 
distinctly described 
their social networks as 
a source of knowledge 
and experience for 
managing chronic 
diseases as well as a 
source of strength 
through their care 
journey 
“Just change of environment really, that's the basics 
right there. And my family helps out a lot. We do a lot 
of things together, talk, and social…For me it was 
environment because I'm from the streets pretty much 
and just to maintain what I have now I have to stay 
away from that atmosphere and I try. I still have some 
friends that are-- but, like I said, I try to for the most 
part stay away from them.” ID023, Class 1  
 
“That's why I talk to certain people, what they going 
through, and I tell them what I'm going through… we'll 
be sharing information for us or what to do, or what type 
of help to get to help each other and whatnot” ID002, 
Class 3  
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Multimorbidity Class  
Subthemes 
Class 1: Low 
Multimorbidity 
(n=9) 
Class 2: Multimorbidity 
(n=5) 




Advice and  
Resources 
The vast majority of participants across the three classes stated that 
providers could not help their patients with substance use cessation, “until 
they were ready.” The participants, however, emphasized the importance for 
providers to remain an open source of care, even for patients with active use 
or relapse 
“Just talk to them. And if you got an individual that has 
taken to you, listening to you, keep going to that person. 
That person might finally change like I did… Because 
everybody has a soul. Everybody has a heart. And like I 
said, show them that you have a heart, put down, don't 
be scared to help them. Don't be scared to stand to talk 
to them. Don't be scared to drink a cup of coffee with 
them or something.” ID006, Class 1 
 
 Class 2 participants 
most consistently 
advised the use of 
incentives as a means 




Half the members 
described either 
MOUD as a means for 
stability that allowed 
them to reduce their 
substance use 
Class 2 was distinct as 
participants discussed 
quitting substance use 
without the use of 
MOUD. Some even 
expressed some 
negative impressions 
regarding MOUD use. 
Nearly all described 
either MOUD or 
treatment for mental 
health comorbidities as 
a means for stability 
that allowed them to 
reduce their substance 
use 
I know people that's been on the methadone program for 
30 years. 30 years! They need to have some kind of 
cutoff. …I didn't take no methadone. I didn't go in no 
detox. I just got tired of being tired. I just told myself, 
"Okay. You'll be sick for a few days. It's better for you 
to be sick for two, or three, or four days than you having 
to go [out wait here?] for months and years and years 
and wondering, do whatever to try to get the drug."  
ID005, Class 2  
 
When I first came there… they were trying to put me on 
the right medication that would stabilize me because I 
was just everywhere at that time. And it took them about 
five years to get me on the right medication. The PRP 
program, and the people there, they were hands on. 
They seen that I needed a little extra help. And they just 
love me. I mean, I have a great personality. Deep down 
inside, I do have a temper. But I help people out. They 




CHAPTER 5: Lessons learned from an explanatory sequential mixed methods study and 
implications for healthcare engagement for people who inject drugs. 
The goal of this study was to understand the needs of people who inject drugs and how 
they engage in care. This is among the few studies to explore the holistic healthcare needs of this 
population as relative to management of multimorbid diseases, substance use, and long-term 
recovery. This chapter discusses the major findings from each study aim, the strengths and 
limitations of the data based papers, and implications of the findings. Additionally, suggestions 
for future research are discussed.  
Summary of Findings 
 
Taken together, the findings of this dissertation found complex healthcare needs for this 
population, described the role of those needs on healthcare engagement, and suggest directions 
for future research, interventions, and policies. Healthcare need was characterized as three 
distinct classes of multimorbidity found with latent class analysis, each with its own implications 
for healthcare utilization and engagement. Findings from quantitative and qualitative analysis 
showed health insurance status did not serve as a barrier to healthcare access, with almost 
ubiquitous coverage in this post-ACA era study. While continuity of care was not associated 
with any class of multimorbidity, interviews with participants highlighted that patient-provider 
relationship, strengthened by integrated care, were important provisions for healthcare 
engagement. Additionally, a subset of participants in qualitative interviews described having 
benefited from focused case management for wrap-around services, particularly those in the 
multimorbidity class co-occurring mental health disorder. Thematic analysis from this class also 
found the importance of mental health stability in order to support management of substance use 
or recovery, and other chronic diseases. Finally, quantitative and qualitative analysis showed 
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prescription of medication for opioid use disorder linked with certain multimorbid classes, 
highlighting it as an important provision for healthcare engagement. Specific findings from each 
study aim are listed below, followed by their implications, including an update to the BMVP to 
better conceptualize engagement in care for future studies. 
 The systematic review presented barriers and facilitators salient to healthcare engagement 
and utilization for PWID with active injecting, highlighting multiple areas. Factors of co-location 
of services, case management, active injection, and patient-provider relationship were associated 
with health utilization and engagement. The factors identified can be utilized by future 
interventions and studies to better integrate the care needs of this population holistically in one 
setting with the goal of reducing the morbidity and mortality associated with injection drug use.  
Aim 2 identified three distinct classes of multimorbidity in an older cohort of current or 
former PWID. Nearly 75% of the sample fell into the classification of having Multimorbidity or 
Multimorbidity with Psychiatric Comorbidity. Individuals in each of these two groups had 
extremely high co-occurring probabilities of all of the diseases we considered with the key 
distinction of additional psychiatric comorbidity in one group. These groups were significantly 
more likely to receive disability, and had higher healthcare utilization, and, while not 
unexpected, had consequences for the healthcare system and these individuals. 
Aim 3 explored engagement within an aging population of current and former people 
who inject drugs from three distinct classes of multimorbidity identified in Aim 2. We used the 
Behavioral Model for Vulnerable Populations to inform the field guide for semi-structured 
interviews and thematic analysis within and between the multimorbid classes. Our findings 
suggest that aspects of healthcare needs and engagement in care are unique in each multimorbid 
class, with some areas of overlap. Participants in all three classes almost entirely felt supported 
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with their current health insurance plans but listed some gaps in coverage. Degree of 
multimorbidity impacted how individuals conceptualized being healthy with respect to their 
healthcare needs and whether perceived and actual needs aligned. Participants in each class listed 
different motivations and sources of information for managing their chronic diseases, with two 
classes emphasizing the need to manage their mental health or active substance use before they 
could manage other multimorbid diseases.  Finally, while specific advice given by participants 
for cessation of substance use differed by each class, participants across all three consistently 
listed that providers could not provide services for cessation to patients, “until they were ready.” 
Strengths and Limitations 
 
There are limitations to within this explanatory sequential mixed methods study (aims 2, 
3). From aim 2, while diseases are measured over a five-year period and most with a 
physiological or biological marker to confirm diagnosis, there were still some disease states that 
were classified by self-report alone. This is a particular limitation with severe psychiatric 
disorders, though classification was based on self-report of diagnosis or prescription of a 
medication. There was also overlap with measurement of diseases over the five-year period and 
the healthcare utilization and health event data, limiting the temporality of associations. 
However, this study’s purpose was to determine the holistic needs of an aging population of 
PWID and not infer causality of multimorbidity class on outcomes. Our study’s restriction to 
participants with study visits in 2014 and first visit in 2018 limited the sample size, though 
sensitivity analysis with all participants with a 2014 visit only indicate a similar 3 class structure 
of multimorbidity. Latent class analysis and finite mixture modeling can be useful tools of 
determining heterogeneity of multimorbidity but future studies should attempt to select diseases 
and classify their states based on an established criteria. One study utilized the Charlson 
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Comorbidity Index when selecting diseases and its measurement, a potential standard for future 
comorbidity studies (Islam et al., 2014). Additionally, HIV was evenly distributed in all three 
classes and was not associated with membership in any class with regressions. This indicates a 
need for future research to conduct a similar analysis but stratify by HIV status. Because this 
data was from an aging population of largely Black, male, and urban population, its findings are 
not generalizable to the larger population of people who inject drugs. Future studies should 
attempt to classify based on severity of disease states and utilize longitudinal data to determine 
transitions of multimorbid disease management. 
There are additional limitations from aim 3. Participants were only eligible for aim 3 if 
they met inclusion criteria for the aim 2, limiting our description only to those surviving for data 
collection between 2014-2018 and with a high number of study visits. Additionally, while there 
was similar distribution for two classes, the number of participants in the Multimorbidity class 
was low (n=5). However, there were 24 interviews conducted in total, with thematic analysis 
consistent across all three classes for many themes. Finally, participants were only able to be 
interviewed once, with some qualitative methodologists suggesting multiple interviews to 
improve trustworthiness of data (Murray et al., 2009; Polkinghorne, 2005). The themes here 
though were confirmed with multiple participants perspectives and between multimorbidity 
classes, and representative of an urban substance using population. Overall, our participants were 
able to relate experiences with healthcare, sampling from classes of multimorbidity, allowing us 
to obtain a holistic understanding of how this aging population engages in their healthcare for 
their complex needs.  
There are important study strengths which offset the limitations. First, the mixed-methods 
design supported an exploration of the complexity nature of healthcare need and engagement for 
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this older population. This approach allows for triangulation of methods to answer the complex 
research question (Creswell & Cresswell, 2018). Additionally, this is the first study to our 
knowledge to expand on the complex healthcare needs of this population, accounting for 
multimorbidity of chronic diseases and substance use disorder as important factors in 
individual’s care trajectories. Aim 2 highlights nuanced patterns of multimorbidity for this 
population that moves beyond the number of diagnosed diseases as they relate to healthcare 
engagement. The exploration within and between classes of multimorbidity highlighted that 
healthcare needs for this population are not homogenous and are associated with utilization of 
healthcare services. Using these classes for purposive sampling provided novel insights into how 
this population engages in healthcare. This mixed-methods approach utilized finite mixture 
modeling as a means for describing healthcare need, served as the basis for sampling, and 
informed aim 3 data collection.  
Implications 
 
 The findings from aim 2 and 3 highlighted areas of need and directions for engagement in 
care for people who inject drugs. Major implications of the findings from this study are presented 
in the domains from the Behavioral Model of Vulnerable Populations.  
Enabling 
 Participants in latent classes with increased multimorbidity were significantly more likely 
to receive disability services (SSI/SSDI) compared to the Low Multimorbidity class. 
Additionally, the Multimorbidity class was significantly more like to have insurance compared to 
the Low Multimorbidity class in bivariate analysis. These findings were echoed during qualitative 
interviews, as participants in all three classes did not report financial barriers to care. Many 
studies have confirmed this, demonstrating a positive association between health insurance and 
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health engagement (Barocas et al., 2014; Hoots, Finlayson, Broz, & Paz-Bailey, 2017; Knowlton 
et al., 2010; Riley et al., 2002; Wilkinson et al., 2007). This evidence could indicate that 
provisions that expand healthcare services, particularly the ACA that expanded Medicaid in 
states like Maryland, where this study was conducted, are particularly important to maintaining 
security with respect to health insurance. Provisions to continue public healthcare insurance and 
receipt of disability services are vital to the subset of this population with increased 
multimorbidity.  
While differences in continuity of care with the same healthcare provider were not found 
with the multimorbidity classes, there were suggestions that this was an important factor that was 
not completely captured by quantitative analysis. Participants listed their patient-provider 
relationship as an important factor in their healthcare engagement, consistent with existing 
literature (Barocas et al., 2014; Biello et al., 2018; Knowlton et al., 2010; Skeer, Ladin, Wilkins, 
Landy, & Stopka, 2018). Having a friendship-like quality to their relationship, potentially 
indicative of long-term care continuity with a provider, was particularly important to the 
multimorbidity class with the highest probability of mental health disorders. Participants in the 
Low Multimorbidity class reported a positive patient-provider relationship when care was 
integrated with one provider. The participants in Multimorbidity with Psychiatric Comorbidity 
echoed a similar sentiment, with particular focus on the desirability of accessing their primary 
care and mental health services in the same location. Co-location of services for this population 
has received increased national attention from policy makers, with a report from the Surgeon 
General listing the growing impetus for integrated care services for this population (US 




 Aim 2’s analysis with LCA demonstrated a significant burden of multimorbid chronic 
diseases. Multiple studies have examined classes of multimorbidity in the general aging 
population using latent class analysis (Gellert et al., 2019; Hall et al., 2018; Hustoft et al., 2013; 
Islam et al., 2014; Olaya et al., 2017; Park, Lee, & Park, 2019; Whitson et al., 2016). While those 
studies and this differ in their selection and measurement of diseases, their findings, like ours, 
demonstrated heterogeneity in multimorbidity. The findings from aim 2 informed sampling for 
aim 3, the findings from which also highlighted themes regarding healthcare engagement based 
on burden of multimorbidity. Participant’s experiences from these interviews indicated that those 
with closer alignment of their perceived and actual needs had greater engagement in care. The 
health constructs were also reflective of the degree of multimorbidity present in the class. The 
Low Multimorbidity class listed their health constructs and needs with respect to preventative 
health behaviors (i.e. quitting smoking, losing weight, etc.) while the Multimorbidity with 
Psychiatric Comorbidity class described specific provisions in their health construct and needs 
with respect to mental health care. Based on participant descriptions, the Health Belief Model 
may offer better constructs to understand these findings. Participants in the Low Multimorbidity 
class had lower level of perceived susceptibility and severity of health problems in contrast to 
those in the Multimorbidity with Psychiatric Comorbidity class. This later class also had high 
perceived susceptibility and severity of disease, particularly with respect to their mental health, 
while also influenced by perceived benefits of seeing their providers and taking actions for their 
health management (Becker, 1974; Champion & Skinner, 2008). 
Health Behaviors  
 Aim 2 findings found that the Multimorbidity class was significantly less likely to report 
injection drug use exclusively compared to the Multimorbidity with Psychiatric Comorbidity 
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class. Other regressions signaled that the Multimorbidity class was less likely and the 
Multimorbidity with Psychiatric Comorbidity class was more likely to engage in substance use, 
but these findings were not significant. These findings taken with aim 3 findings indicate that 
health behaviors from chronic disease and substance use management varied across classes and 
were likely a function of the multimorbidity class. 
  Participants in their Multimorbidity with Psychiatric Comorbidity class in particular listed 
the care team and wrap around services as useful for their healthcare engagement, particularly 
for their mental health.  Wrap-around services provide linkage to services including disability, 
housing, and social worker support. (Kay & Westfall, 2020). These services, however, are not 
often available at all clinic facilities and are often limited when available. The Comprehensive 
Addiction Resources Emergency (CARE) Act provides funding to health centers and systems for 
hiring clinicians and ancillary healthcare workers to provide these wrap-around services and 
improve engagement in care, particularly for the vulnerable subset of individuals with co-
occurring mental health disorders (H.R.2569, 2019). Legislation of this nature expands much 
needed services that are often underfunded but were highlighted by study participants as 
necessary resources utilized for healthcare engagement.  
The participants in the Multimorbidity with Psychiatric Comorbidity also listed the need 
to stabilize their mental health as a provision for cessation from substance use and injection. 
Multiple studies have shown that substance use and mental health disorders are highly correlated 
(Kelly & Daley, 2013; Klinkenberg & Sacks, 2004; Ross & Peselow, 2012). The Multimorbidity 
with Psychiatric Comorbidity was the only class with high odds of both outpatient and 
emergency room utilization from aim 2 analysis. While no study could be located to confirm our 
findings of a participant descriptions of stabilizing mental health as a means for substance use 
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cessation, some studies identified an unmet treatment need for individuals with triple diagnosis 
of substance use disorder, mental health disorder, and chronic disease. There is also some 
evidence demonstrating an improvement of chronic disease management following treatment for 
mental health disorder (Klinkenberg & Sacks, 2004; Tegger et al., 2008).  
 The Multimorbidity with Psychiatric Comorbidity class was significantly more likely than 
the Low Multimorbidity class to received medication for opioid use disorder. The use of MOUD 
varied across class, with participants in the Multimorbidity class listing non-medication strategies 
for recovery and even expressing some stigma against those who required medications. While 
not directly reported by participants, their language mirrored some language from 12-step 
programs, where there has been a persistent cultural stigma against those who utilize MOUD.  
Despite this, there is robust evidence of the benefits of MOUD, confirmed by participants in the 
Low Multimorbidity and Multimorbidity with Psychiatric Comorbidity class (Islam et al., 2013; 
Mehta et al., 2015; Miller et al., 2018; Morozova, Dvoriak, Pykalo, & Altice, 2017; Parmenter et 
al., 2013; Wang et al., 2013). Primary and integrated care facilities should provide MOUD for 
individuals with current or recovering substance use (DHHS, 2016). Additionally, there is 
evidence that peer based support groups, similar to 12 step programs, can play a role in long term 
recovery when they provide a holistic and non-stigmatized environment for participants 
(Krawczyk, Negron, Nieto, Agus, & Fingerhood, 2018). Finally, lack of providers with licenses 
to prescribe MOUD or limitations to the number of patients for whom they can prescribe has 
been shown to be a barrier to MOUD access for this population (Marino et al., 2019). Given 
participant’s clear indication of MOUD as a provision for healthcare engagement, future 
legislation should remove barriers that healthcare providers face and allow for a seamless 




Recommendations for Future Research 
 
  The Behavioral Model for Vulnerable Populations provides a guiding framework and 
conceptualization of factors in the aims of this study. However, there are two shortcomings of 
this model. The first is that it is adapted from a model with healthcare utilization as the main 
outcome. While later iterations of both the Andersen and BMVP models state their model 
captures other facets related to engagement in care with variables of satisfaction and preferences, 
it cannot justify being a healthcare engagement model without indicators of disease management. 
Second, the BMVP falls short in its conceptualization of the Need domain as it does not describe 
the relationship between perceived and actual needs and how this domain relates to healthcare 
outcomes. While no model exists to capture engagement in care, the Health Belief Model may 
offer better constructs to understand the Need gaps in the BMVP (Becker, 1974; Champion & 
Skinner, 2008). Figure 1 presents an update to the BMVP that incorporates elements of the 
Health Belief model that better conceptualize the Need based domain. Updates are the inclusion 
of perceived susceptibility and severity of disease, and perceived benefits and barriers as factors 
within the Needs domains (Becker, 1974; Champion & Skinner, 2008).   
 While no model exists to fully capture the full extent of engagement in care, especially 
with respect to disease management, there are methods available to better understand how 
individuals control and manage multimorbid diseases and substance use over time. First, given 
HIV and viral load suppression status were not associated with any of the multimorbidity classes, 
it is necessary to conduct similar analysis stratifying by HIV status to determine if 
multimorbidity and disease burden differ by HIV status. Additionally, using a similar approach 
to the latent class analysis presented here, latent trait analysis can utilize biological, 
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physiological, and psychometric indicators of disease and substance use control to highlight 
patterns in disease management. Utilizing this to better define actual need from the BMVP, then 
conduct qualitative interviews, ideally multiple interviews, with individuals from each profile of 
multimorbid disease control will enable enhanced triangulation of engagement in care for this 
population with better depth and precision.  
 Finally, further research should be completed targeting with the Multimorbidity with 
Psychiatric Comorbidity class. While this study was conducted with an overall vulnerable 
population, this class has increased vulnerability, as evidenced by the high burden of disease, 
utilization of emergency room services, and complex need and experiences with healthcare 
engagement described in qualitative interviews. While the BMVP with domains of the Health 
Belief model can provide global guidance on study conceptualization and framing, studies with 
this group should be pursued with an additional syndemic framework given the complicated but 
very evident relationship between mental health disorders and substance use. This group in 
particular during qualitative interviews indicated the need to stabilize their mental health prior to 
engaging in any other facet of their care. However, they also indicated the complicated nature of 
this process, and potential survival bias was also a potential issue in our findings. Future research 
will benefit from a broader age range in this class to understand the experiences with 
management of mental health and substance use over time and the interventions that can be 
applied earlier in life to prevent excess morbidity and mortality.  
Conclusion 
 
As current or former PWID seek healthcare, their needs extend beyond the traditional 
realms of substance use. This study demonstrates heterogeneity in multimorbidity for PWID with 
distinct latent classes. Two of these classes of multimorbidity indicate greater healthcare need as 
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well as interventions designed to improve engagement. Additionally, there is a large subsample 
of the population that has an enhanced need for care because of co-occurring mental health 
disorders. Clinicians can capitalize on the implications for each class, tailoring follow-up and 
care services to best address the needs of multimorbidity classes. Better understanding of 
participant’s perceptions for optimal healthcare engagement can provide additional avenues for 
interventions and leverage strengths for sustained engagement.  
Participants in this study highlighted multiple avenues for healthcare engagement, 
including positive patient-provider relationships, sustained health insurance, alignment of their 
healthcare needs with those designated by healthcare providers, and receipt of integrated care 
capable of address pressing health needs. Policy considerations include the continued provision 
of low barrier access to publicly available insurance, passage of legislation that provides funding 
for clinics to provide wrap-around services to individuals with substance use disorder, and 
removing MOUD prescription barriers. Finally, this study affirms the importance of healthcare 
meeting the needs of this population at the level they are able to accept care. Holistic healthcare 
systems can address these needs best with integrated care systems that provide for harm 
reduction, co-location with substance use and mental health treatment, and wrap around services, 
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Field Guide for Qualitative Interviews 
 
Thank you for agreeing to participate in this interview. Remember, you do not have to answer 
any questions that make you feel uncomfortable and you can discontinue this interview at any 
time.  
 
Domain: Enabling Factors 
Overarching Question: What enabling factors act as facilitators or barriers to engagement in 
care? 
 
• Tell me about what’s happening in your life currently? (Probe: Any changes in work/ 












• Tell me about the last time you went to see the doctor or a health care provider 














• Tell me about the place you normally go to seek health care, whatever that means to 
you 








• What has your experience been with the staff there? (Probe: The receptionist, medical 
assistants, nurses, pharmacists, etc.) (Probe: Can you tell me what they do that is 


















• Can you tell me about financial barriers in receiving care? (Probe: Do you have to pay 
when you get care? Is there copay? Did insurance cover the costs? How did you get 














Domain: Need Factors and Outcomes  
Overarching Question: How an individual conceptualize their health needs, meet those 
needs, and its relationship with satisfaction/engagement with care? 
 


























• Tell me about your top health concerns (Probe: What are some illnesses that you need 

































































Domain: Health Behaviors  
Overarching Question: What are an individual’s personal health practices and substance use 
and how to they relate to overall engagement in care?  
 
• How does/did your care impact your substance use? (Probe: Can you tell me whether 





























Latent class analysis .do file  
 
***Create a variable that lists the year of the visit 
gen year=yofd(visdate) 
 
***Create a variable that tags all ids with a visit in 2018 
bysort id (year): egen tokeep = max(year==2018) 
 
***Create a variable that tags all ids with a visit in 2014 
bysort id (year): egen tokeep2= max(year==2014) 
 
***Create a variable where 2 represents those who had a visit in 2014 & 18 
gen tokeep3=tokeep+tokeep2 
 
***Drop those with a tokeep2<2 
drop if tokeep3<2 
 
***Drop all observations before 2014 
drop if year<2014 
 
 
bys id (visdate): gen n=_n 
 
rename samedoc2 samedocx 
 
***Fibrosis in long form*** 
gen fibrosis=. 
replace fibrosis=1 if fbscan<=7 
replace fibrosis=2 if fbscan>7 
replace fibrosis=3 if fbscan>=9.5 
replace fibrosis=4 if fbscan>=12.5 
replace fibrosis=. if fbscan==. 
 
***covariates that are date dependent done in long form*** 
foreach v in m0f1 beduc age black cigyn alcyn auditcat mj crack snrtcoc injcoc spdbal smkher 
snrther injher curuser ivstat abusescr prscrbmeth prscrbbup prscrbnalt samedoc samedocx er6m 
outpat6m inpat6m inclt5k insur6m imcare6m imcaid6m ipriv6m share bmimedh disability od 
odfreq hivvl50 { 
 bysort id (visdate): egen `v'_cov=max(`v') if n==1 
 bysort id (visdate): egen `v'_cov_fin=max(`v'_cov) 
 } 







keep id n black visdate hba1c chol bpsys bpdias hiv diabtx6m hcholtx6m hbptx6m hrtpbtx6m 
renaltx6m lungdxtx6m copd maxfev fev_fvc hcvvis cesd23 gfr_naa gfr_aa hrt6m hrt6m_N 
samedoc samedocx er6m outpat6m inpat6m outer6m evrskininfct blskininfct6m evrhrtdx 
blhrtdx6m evrmyoinfrct blmyoinfrct6m evrhrtfail blhrtfail6m evrstroke blstroke6m evrarthritis 
blarthritis6m evrcancer blcancer6m evrpneuma blpneum6m evrspsis blsepsis6m evrendo 
blendo6m emeddep depdx6m deptx6m emedanx anxdx6m anxtx6m emedmand manddx6m 
mandtx6m emedschi schidx6m schitx6m ehspmntl thoughts plan attempt skininfct6m hrtdx6m 
myoinfrct6m hrtfail6m stroke6m arthritis6m pneum6m sepsis6m endo6m fbscan fibrosis 
m0f1_cov_fin beduc_cov_fin age_cov_fin black_cov_fin cigyn_cov_fin alcyn_cov_fin 
auditcat_cov_fin mj_cov_fin crack_cov_fin snrtcoc_cov_fin injcoc_cov_fin spdbal_cov_fin 
smkher_cov_fin snrther_cov_fin injher_cov_fin curuser_cov_fin ivstat_cov_fin 
abusescr_cov_fin prscrbmeth_cov_fin prscrbbup_cov_fin prscrbnalt_cov_fin samedoc_cov_fin 
samedocx_cov_fin er6m_cov_fin outpat6m_cov_fin inpat6m_cov_fin inclt5k_cov_fin 
insur6m_cov_fin imcare6m_cov_fin imcaid6m_cov_fin ipriv6m_cov_fin share_cov_fin 
bmimedh_cov_fin od odfreq disability hivvl50 hivvl50_cov_fin 
 
reshape wide black visdate hba1c chol bpsys bpdias hiv diabtx6m hcholtx6m hbptx6m 
hrtpbtx6m renaltx6m lungdxtx6m copd maxfev fev_fvc hcvvis cesd23 gfr_naa gfr_aa hrt6m 
hrt6m_N samedoc samedocx er6m outpat6m inpat6m outer6m evrskininfct blskininfct6m 
evrhrtdx blhrtdx6m evrmyoinfrct blmyoinfrct6m evrhrtfail blhrtfail6m evrstroke blstroke6m 
evrarthritis blarthritis6m evrcancer blcancer6m evrpneuma blpneum6m evrspsis blsepsis6m 
evrendo blendo6m emeddep depdx6m deptx6m emedanx anxdx6m anxtx6m emedmand 
manddx6m mandtx6m emedschi schidx6m schitx6m ehspmntl thoughts plan attempt skininfct6m 
hrtdx6m myoinfrct6m hrtfail6m stroke6m arthritis6m pneum6m sepsis6m endo6m fbscan 
fibrosis m0f1_cov_fin beduc_cov_fin age_cov_fin black_cov_fin cigyn_cov_fin alcyn_cov_fin 
auditcat_cov_fin mj_cov_fin crack_cov_fin snrtcoc_cov_fin injcoc_cov_fin spdbal_cov_fin 
smkher_cov_fin snrther_cov_fin injher_cov_fin curuser_cov_fin ivstat_cov_fin 
abusescr_cov_fin prscrbmeth_cov_fin prscrbbup_cov_fin prscrbnalt_cov_fin samedoc_cov_fin 
samedocx_cov_fin er6m_cov_fin outpat6m_cov_fin inpat6m_cov_fin inclt5k_cov_fin 
insur6m_cov_fin imcare6m_cov_fin imcaid6m_cov_fin ipriv6m_cov_fin share_cov_fin 




foreach v in hba1c1 hba1c2 hba1c3 hba1c4 hba1c5 hba1c6 hba1c7 hba1c8 hba1c9 { 
 gen diabetes`v'=`v' 
 replace diabetes`v'=1 if `v'>=6.5 
 replace diabetes`v'=0 if `v'<6.5 




***replace missing values with 0 
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foreach v in diabtx6m1 diabtx6m2 diabtx6m3 diabtx6m4 diabtx6m5 diabtx6m6 diabtx6m7 
diabtx6m8 diabtx6m9 { 




gen diabetic= diabeteshba1c1+ diabeteshba1c2+ diabeteshba1c3+ diabeteshba1c4+ 






replace diabetic_final=1 if diabetic>=1 





***Obstructive airway  
foreach v in copd1 copd2 copd3 copd4 copd5 copd6 copd7 copd8 copd9 { 
 gen copd`v'=`v' 
 replace copd`v'=1 if `v'==1 
 replace copd`v'=0 if `v'==0 




foreach v in lungdxtx6m1 lungdxtx6m2 lungdxtx6m3 lungdxtx6m4 lungdxtx6m5 lungdxtx6m6 
lungdxtx6m7 lungdxtx6m8 lungdxtx6m9 { 












replace ob_air_final=1 if ob_air>=1 




egen ob_air2= rowtotal(copdcopd1 copdcopd2 copdcopd3 copdcopd4 copdcopd5 copdcopd6 
copdcopd7 copdcopd8 copdcopd9) 
gen ob_air2_final=ob_air2 
replace ob_air2_final=1 if ob_air2>=1 
replace ob_air2_final=0 if ob_air2==0 
 
gen ob2_air=.  
replace ob2_air=1 if copdcopd1==1 & copdcopd2==1 
replace ob2_air=1 if copdcopd2==1 & copdcopd3==1 
replace ob2_air=1 if copdcopd3==1 & copdcopd4==1 
replace ob2_air=1 if copdcopd4==1 & copdcopd5==1 
replace ob2_air=1 if copdcopd5==1 & copdcopd6==1 
replace ob2_air=1 if copdcopd6==1 & copdcopd7==1 
replace ob2_air=1 if copdcopd7==1 & copdcopd8==1 
replace ob2_air=1 if copdcopd8==1 & copdcopd9==1 
gen ob_air3_final=ob2_air 
replace ob_air3_final=1 if ob2_air>=1 
replace ob_air3_final=0 if ob2_air<1 
 
 
***50% COPD!  
***hiv 
foreach v in hiv1 hiv2 hiv3 hiv4 hiv5 hiv6 hiv7 hiv8 hiv9 { 
 gen hiv`v'=`v' 
 replace hiv`v'=1 if `v'==1 
 replace hiv`v'=0 if `v'==0 




foreach v in hrt6m1 hrt6m2 hrt6m3 hrt6m4 hrt6m5 hrt6m6 hrt6m7 hrt6m8 hrt6m9 { 











replace hiv_final=1 if hiv_tot>=1 
replace hiv_final=0 if hiv_tot==0 
 





foreach v in hcvvis1 hcvvis2 hcvvis3 hcvvis4 hcvvis5 hcvvis6 hcvvis7 hcvvis8 hcvvis9 { 
 gen hcv`v'=`v' 
 replace hcv`v'=1 if `v'==1 
 replace hcv`v'=0 if `v'==0 









replace hcv_final=1 if hcv_tot>=1 
replace hcv_final=0 if hcv_tot==0 
 
***80% with HCV ab 




replace sys=1 if bpsys1>=140 & bpsys2>=140  
replace sys=1 if bpsys2>=140 & bpsys3>=140  
replace sys=1 if bpsys3>=140 & bpsys4>=140 
replace sys=1 if bpsys4>=140 & bpsys5>=140  
replace sys=1 if bpsys5>=140 & bpsys6>=140   
replace sys=1 if bpsys6>=140 & bpsys7>=140  
replace sys=1 if bpsys7>=140 & bpsys8>=140 
replace sys=1 if bpsys8>=140 & bpsys9>=140   
 
gen dias=. 
replace dias=1 if bpdias1>=90 & bpdias2>=90 
replace dias=1 if bpdias2>=90 & bpdias3>=90 
replace dias=1 if bpdias3>=90 & bpdias4>=90 
replace dias=1 if bpdias4>=90 & bpdias5>=90 
replace dias=1 if bpdias5>=90 & bpdias6>=90 
replace dias=1 if bpdias6>=90 & bpdias7>=90 
replace dias=1 if bpdias7>=90 & bpdias8>=90 
replace dias=1 if bpdias8>=90 & bpdias9>=90 
 
egen htn_tx= rowtotal(hbptx6m1 hbptx6m2 hbptx6m3 hbptx6m4 hbptx6m5 hbptx6m6 
hbptx6m7 hbptx6m8 hbptx6m9) 




egen htn= rowtotal(sys dias htn_tx) 
gen htn_final=htn 
replace htn_final=1 if htn>=1 




***replace missing values with 0 
foreach v in cesd231 cesd232 cesd233 cesd234 cesd235 cesd236 cesd237 cesd238 cesd239 
depdx6m1 depdx6m2 depdx6m3 depdx6m4 depdx6m5 depdx6m6 depdx6m7 depdx6m8 
depdx6m9 deptx6m1 deptx6m2 deptx6m3 deptx6m4 deptx6m5 deptx6m6 deptx6m7 deptx6m8 
deptx6m9 emeddep1 emeddep2 emeddep3 emeddep4 emeddep5 emeddep6 emeddep7 emeddep8 
emeddep9 { 




egen depression_dx= rowtotal(cesd231 cesd232 cesd233 cesd234 cesd235 cesd236 cesd237 
cesd238 cesd239 depdx6m1 depdx6m2 depdx6m3 depdx6m4 depdx6m5 depdx6m6 depdx6m7 
depdx6m8 depdx6m9 deptx6m1 deptx6m2 deptx6m3 deptx6m4 deptx6m5 deptx6m6 deptx6m7 
deptx6m8 deptx6m9 emeddep1 emeddep2 emeddep3 emeddep4 emeddep5 emeddep6 emeddep7 
emeddep8 emeddep9) 
gen depression_final=depression 
replace depression_final=1 if depression_dx>=1 





***every renaldx and renaldx6m are missing 
foreach v in renaltx6m1 renaltx6m2 renaltx6m3 renaltx6m4 renaltx6m5 renaltx6m6 renaltx6m7 
renaltx6m8 renaltx6m9 { 





replace gfr=1 if gfr_aa1<60 & black1==1 
replace gfr=1 if gfr_aa2<60 & black1==1 
replace gfr=1 if gfr_aa3<60 & black1==1 
replace gfr=1 if gfr_aa4<60 & black1==1 
replace gfr=1 if gfr_aa5<60 & black1==1 
replace gfr=1 if gfr_aa6<60 & black1==1 
replace gfr=1 if gfr_aa7<60 & black1==1 
replace gfr=1 if gfr_aa8<60 & black1==1 
replace gfr=1 if gfr_aa9<60 & black1==1 
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replace gfr=1 if gfr_naa1<60 & black1==0 
replace gfr=1 if gfr_naa2<60 & black1==0 
replace gfr=1 if gfr_naa3<60 & black1==0 
replace gfr=1 if gfr_naa4<60 & black1==0 
replace gfr=1 if gfr_naa5<60 & black1==0 
replace gfr=1 if gfr_naa6<60 & black1==0 
replace gfr=1 if gfr_naa7<60 & black1==0 
replace gfr=1 if gfr_naa8<60 & black1==0 
replace gfr=1 if gfr_naa9<60 & black1==0 
replace gfr=0 if gfr==. 
 
egen renal_dx=rowtotal(renaltx6m1 renaltx6m2 renaltx6m3 renaltx6m4 renaltx6m5 renaltx6m6 
renaltx6m7 renaltx6m8 renaltx6m9 gfr) 
gen renal_final=renal_dx 
replace renal_final=1 if renal_dx>=1 
replace renal_final=0 if renal_dx==0 
 
****Anxiety**** 
foreach v in anxdx6m1 anxdx6m2 anxdx6m3 anxdx6m4 anxdx6m5 anxdx6m6 anxdx6m7 
anxdx6m8 anxdx6m9 anxtx6m1 anxtx6m2 anxtx6m3 anxtx6m4 anxtx6m5 anxtx6m6 anxtx6m7 
anxtx6m8 anxtx6m9 emedanx1 emedanx2 emedanx3 emedanx4 emedanx5 emedanx6 emedanx7 
emedanx8 emedanx9 { 




egen anxiety_dx=rowtotal(anxdx6m1 anxdx6m2 anxdx6m3 anxdx6m4 anxdx6m5 anxdx6m6 
anxdx6m7 anxdx6m8 anxdx6m9 anxtx6m1 anxtx6m2 anxtx6m3 anxtx6m4 anxtx6m5 anxtx6m6 
anxtx6m7 anxtx6m8 anxtx6m9 emedanx1 emedanx2 emedanx3 emedanx4 emedanx5 emedanx6 
emedanx7 emedanx8 emedanx9) 
gen anxiety_final=anxiety_dx 
replace anxiety_final=1 if anxiety_dx>=1 
replace anxiety_final=0 if anxiety_dx==0 
 
****Manic Depression**** 
foreach v in emedmand1 emedmand2 emedmand3 emedmand4 emedmand5 emedmand6 
emedmand7 emedmand8 emedmand9 manddx6m1 manddx6m2 manddx6m3 manddx6m4 
manddx6m5 manddx6m6 manddx6m7 manddx6m8 manddx6m9 mandtx6m1 mandtx6m2 
mandtx6m3 mandtx6m4 mandtx6m5 mandtx6m6 mandtx6m7 mandtx6m8 mandtx6m9 { 




egen bipolar_dx=rowtotal(emedmand1 emedmand2 emedmand3 emedmand4 emedmand5 
emedmand6 emedmand7 emedmand8 emedmand9 manddx6m1 manddx6m2 manddx6m3 
manddx6m4 manddx6m5 manddx6m6 manddx6m7 manddx6m8 manddx6m9 mandtx6m1 
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mandtx6m2 mandtx6m3 mandtx6m4 mandtx6m5 mandtx6m6 mandtx6m7 mandtx6m8 
mandtx6m9) 
gen bipolar_final=bipolar_dx 
replace bipolar_final=1 if bipolar_dx>=1 
replace bipolar_final=0 if bipolar_dx==0 
 
****Schizophrenia**** 
foreach v in emedschi1 emedschi2 emedschi3 emedschi4 emedschi5 emedschi6 emedschi7 
emedschi8 emedschi9 schidx6m1 schidx6m2 schidx6m3 schidx6m4 schidx6m5 schidx6m6 
schidx6m7 schidx6m8 schidx6m9 schitx6m1 schitx6m2 schitx6m3 schitx6m4 schitx6m5 
schitx6m6 schitx6m7 schitx6m8 schitx6m9 { 




egen schizophrenia_dx=rowtotal(emedschi1 emedschi2 emedschi3 emedschi4 emedschi5 
emedschi6 emedschi7 emedschi8 emedschi9 schidx6m1 schidx6m2 schidx6m3 schidx6m4 
schidx6m5 schidx6m6 schidx6m7 schidx6m8 schidx6m9 schitx6m1 schitx6m2 schitx6m3 
schitx6m4 schitx6m5 schitx6m6 schitx6m7 schitx6m8 schitx6m9) 
gen schizophrenia_final=schizophrenia_dx 
replace schizophrenia_final=1 if schizophrenia_dx>=1 
replace schizophrenia_final=0 if schizophrenia_dx==0 
 
****Athritis**** 
foreach v in  evrarthritis1 evrarthritis2 evrarthritis3 evrarthritis4 evrarthritis5 evrarthritis6 
evrarthritis7 evrarthritis8 evrarthritis9 arthritis6m1 arthritis6m2 arthritis6m3 arthritis6m4 
arthritis6m5 arthritis6m6 arthritis6m7 arthritis6m8 arthritis6m9 blarthritis6m1 blarthritis6m2 
blarthritis6m3 blarthritis6m4 blarthritis6m5 blarthritis6m6 blarthritis6m7 blarthritis6m8 
blarthritis6m9 { 




egen arthritis_dx=rowtotal(evrarthritis1 evrarthritis2 evrarthritis3 evrarthritis4 evrarthritis5 
evrarthritis6 evrarthritis7 evrarthritis8 evrarthritis9 arthritis6m1 arthritis6m2 arthritis6m3 
arthritis6m4 arthritis6m5 arthritis6m6 arthritis6m7 arthritis6m8 arthritis6m9 blarthritis6m1 
blarthritis6m2 blarthritis6m3 blarthritis6m4 blarthritis6m5 blarthritis6m6 blarthritis6m7 
blarthritis6m8 blarthritis6m9) 
gen arthritis_final=arthritis_dx 
replace arthritis_final=1 if arthritis_dx>=1 
replace arthritis_final=0 if arthritis_dx==0 
 
***collapsing Bipolar and Schizophrenia**** 
egen major_psych=rowtotal(bipolar_final schizophrenia_final) 
generate major_psych_final=major_psych 






replace depress=1 if cesd231==1 & cesd232==1 
replace depress=1 if cesd232==1 & cesd233==1 
replace depress=1 if cesd233==1 & cesd234==1 
replace depress=1 if cesd234==1 & cesd235==1 
replace depress=1 if cesd235==1 & cesd236==1 
replace depress=1 if cesd236==1 & cesd237==1 
replace depress=1 if cesd237==1 & cesd238==1 
replace depress=1 if cesd238==1 & cesd231==1 
 
gen depress2=depress 
replace depress2=0 if depress==. 
 
****Composite Anxiety and Depression**** 
egen ad_stringent=rowtotal(depress anxiety_final) 
gen ad_stringent_final=ad_stringent 
replace ad_stringent_final=1 if ad_stringent>=1 
 
egen ad_relax=rowtotal(depression_final anxiety_final) 
gen ad_relax_final=ad_relax 
replace ad_relax_final=1 if ad_relax>=1 
 
***fibrosis*** 
egen fibrosis_final=rowmax(fibrosis1 fibrosis2 fibrosis3 fibrosis4 fibrosis5 fibrosis6 fibrosis7 
fibrosis8 fibrosis9) 
replace fibrosis_final=-9 if fibrosis_final==. 
 
gen fibrosis_mplus=fibrosis_final 
replace fibrosis_mplus=1 if fibrosis_final>=3 
replace fibrosis_mplus=0 if fibrosis_final<3 
replace fibrosis_mplus=-9 if fibrosis_final==-9 
 
egen fibrosis2_final=rowmedian(fibrosis1 fibrosis2 fibrosis3 fibrosis4 fibrosis5 fibrosis6 
fibrosis7 fibrosis8 fibrosis9) 
replace fibrosis2_final=-9 if fibrosis_final==. 
 
gen fibrosis2_mplus=fibrosis2_final 
replace fibrosis2_mplus=1 if fibrosis_final>=3 
replace fibrosis2_mplus=0 if fibrosis_final<3 
replace fibrosis2_mplus=-9 if fibrosis_final==-9 
 
***Covariates in wide form*** 
egen m0f1_mplus=rowmax(m0f1_cov_fin1 m0f1_cov_fin2 m0f1_cov_fin3 m0f1_cov_fin4 




egen beduc_mplus=rowmax(beduc_cov_fin1 beduc_cov_fin2 beduc_cov_fin3 beduc_cov_fin4 
beduc_cov_fin5 beduc_cov_fin6 beduc_cov_fin7 beduc_cov_fin8 beduc_cov_fin9) 
 
egen age2=rowmax(age_cov_fin1 age_cov_fin2 age_cov_fin3 age_cov_fin4 age_cov_fin5 
age_cov_fin6 age_cov_fin7 age_cov_fin8 age_cov_fin9) 
 
gen age_mplus=age2 
replace age_mplus=0 if age2<55 
replace age_mplus=1 if age2>=55 
 
egen black_mplus=rowmax(black_cov_fin1 black_cov_fin2 black_cov_fin3 black_cov_fin4 
black_cov_fin5 black_cov_fin6 black_cov_fin7 black_cov_fin8 black_cov_fin9) 
 
egen cigyn_mplus=rowmax(cigyn_cov_fin1 cigyn_cov_fin2 cigyn_cov_fin3 cigyn_cov_fin4 
cigyn_cov_fin5 cigyn_cov_fin6 cigyn_cov_fin7 cigyn_cov_fin8 cigyn_cov_fin9) 
 
egen alcyn_mplus=rowmax(alcyn_cov_fin1 alcyn_cov_fin2 alcyn_cov_fin3 alcyn_cov_fin4 
alcyn_cov_fin5 alcyn_cov_fin6 alcyn_cov_fin7 alcyn_cov_fin8 alcyn_cov_fin9) 
 
egen auditcat_mplus=rowmax(auditcat_cov_fin1 auditcat_cov_fin2 auditcat_cov_fin3 
auditcat_cov_fin4 auditcat_cov_fin5 auditcat_cov_fin6 auditcat_cov_fin7 auditcat_cov_fin8 
auditcat_cov_fin9) 
 
egen mj_mplus=rowmax(mj_cov_fin1 mj_cov_fin2 mj_cov_fin3 mj_cov_fin4 mj_cov_fin5 
mj_cov_fin6 mj_cov_fin7 mj_cov_fin8 mj_cov_fin9) 
 
egen crack_mplus=rowmax(crack_cov_fin1 crack_cov_fin2 crack_cov_fin3 crack_cov_fin4 
crack_cov_fin5 crack_cov_fin6 crack_cov_fin7 crack_cov_fin8 crack_cov_fin9) 
 
egen snrtcoc_mplus=rowmax(snrtcoc_cov_fin1 snrtcoc_cov_fin2 snrtcoc_cov_fin3 
snrtcoc_cov_fin4 snrtcoc_cov_fin5 snrtcoc_cov_fin6 snrtcoc_cov_fin7 snrtcoc_cov_fin8 
snrtcoc_cov_fin9) 
 
egen injcoc_mplus=rowmax(injcoc_cov_fin1 injcoc_cov_fin2 injcoc_cov_fin3 injcoc_cov_fin4 
injcoc_cov_fin5 injcoc_cov_fin6 injcoc_cov_fin7 injcoc_cov_fin8 injcoc_cov_fin9) 
 
egen spdbal_mplus=rowmax(spdbal_cov_fin1 spdbal_cov_fin2 spdbal_cov_fin3 
spdbal_cov_fin4 spdbal_cov_fin5 spdbal_cov_fin6 spdbal_cov_fin7 spdbal_cov_fin8 
spdbal_cov_fin9) 
 
egen smkher_mplus=rowmax(smkher_cov_fin1 smkher_cov_fin2 smkher_cov_fin3 





egen snrther_mplus=rowmax(snrther_cov_fin1 snrther_cov_fin2 snrther_cov_fin3 
snrther_cov_fin4 snrther_cov_fin5 snrther_cov_fin6 snrther_cov_fin7 snrther_cov_fin8 
snrther_cov_fin9) 
 
egen injher_mplus=rowmax(injher_cov_fin1 injher_cov_fin2 injher_cov_fin3 injher_cov_fin4 
injher_cov_fin5 injher_cov_fin6 injher_cov_fin7 injher_cov_fin8 injher_cov_fin9) 
 
egen curuser_mplus=rowmax(curuser_cov_fin1 curuser_cov_fin2 curuser_cov_fin3 
curuser_cov_fin4 curuser_cov_fin5 curuser_cov_fin6 curuser_cov_fin7 curuser_cov_fin8 
curuser_cov_fin9) 
 
egen ivstat_mplus=rowmax(ivstat_cov_fin1 ivstat_cov_fin2 ivstat_cov_fin3 ivstat_cov_fin4 
ivstat_cov_fin5 ivstat_cov_fin6 ivstat_cov_fin7 ivstat_cov_fin8 ivstat_cov_fin9) 
 
egen abusecr_mplus=rowmax(abusescr_cov_fin1 abusescr_cov_fin2 abusescr_cov_fin3 
abusescr_cov_fin4 abusescr_cov_fin5 abusescr_cov_fin6 abusescr_cov_fin7 abusescr_cov_fin8 
abusescr_cov_fin9) 
 
egen prscrbmeth_mplus=rowmax(prscrbmeth_cov_fin1 prscrbmeth_cov_fin2 
prscrbmeth_cov_fin3 prscrbmeth_cov_fin4 prscrbmeth_cov_fin5 prscrbmeth_cov_fin6 
prscrbmeth_cov_fin7 prscrbmeth_cov_fin8 prscrbmeth_cov_fin9) 
 
egen prscrbbup_mplus=rowmax(prscrbbup_cov_fin1 prscrbbup_cov_fin2 prscrbbup_cov_fin3 
prscrbbup_cov_fin4 prscrbbup_cov_fin5 prscrbbup_cov_fin6 prscrbbup_cov_fin7 
prscrbbup_cov_fin8 prscrbbup_cov_fin9) 
 
egen prscrbnalt_mplus=rowmax(prscrbnalt_cov_fin1 prscrbnalt_cov_fin2 prscrbnalt_cov_fin3 
prscrbnalt_cov_fin4 prscrbnalt_cov_fin5 prscrbnalt_cov_fin6 prscrbnalt_cov_fin7 
prscrbnalt_cov_fin8 prscrbnalt_cov_fin9) 
 
egen ost=rowmax(prscrbmeth_cov_fin1 prscrbmeth_cov_fin2 prscrbmeth_cov_fin3 
prscrbmeth_cov_fin4 prscrbmeth_cov_fin5 prscrbmeth_cov_fin6 prscrbmeth_cov_fin7 
prscrbmeth_cov_fin8 prscrbmeth_cov_fin9 prscrbbup_cov_fin1 prscrbbup_cov_fin2 
prscrbbup_cov_fin3 prscrbbup_cov_fin4 prscrbbup_cov_fin5 prscrbbup_cov_fin6 
prscrbbup_cov_fin7 prscrbbup_cov_fin8 prscrbbup_cov_fin9 prscrbnalt_cov_fin1 
prscrbnalt_cov_fin2 prscrbnalt_cov_fin3 prscrbnalt_cov_fin4 prscrbnalt_cov_fin5 
prscrbnalt_cov_fin6 prscrbnalt_cov_fin7 prscrbnalt_cov_fin8 prscrbnalt_cov_fin9) 
generate ost_mplus=ost 
replace ost_mplus=1 if ost>=1 
replace ost_mplus=0 if ost==0 
 
egen samedoc_mplus=rowmax(prscrbnalt_cov_fin1 prscrbnalt_cov_fin2 prscrbnalt_cov_fin3 





egen samedocx_mplus=rowmax(samedocx_cov_fin1 samedocx_cov_fin2 samedocx_cov_fin3 
samedocx_cov_fin4 samedocx_cov_fin5 samedocx_cov_fin6 samedocx_cov_fin7 
samedocx_cov_fin8 samedocx_cov_fin9) 
 
egen er6m_mplus=rowmax(er6m_cov_fin1 er6m_cov_fin2 er6m_cov_fin3 er6m_cov_fin4 
er6m_cov_fin5 er6m_cov_fin6 er6m_cov_fin7 er6m_cov_fin8 er6m_cov_fin9) 
 
egen outpat_mplus=rowmax(outpat6m_cov_fin1 outpat6m_cov_fin2 outpat6m_cov_fin3 
outpat6m_cov_fin4 outpat6m_cov_fin5 outpat6m_cov_fin6 outpat6m_cov_fin7 
outpat6m_cov_fin8 outpat6m_cov_fin9) 
 
egen inpat_mplus=rowmax(inpat6m_cov_fin1 inpat6m_cov_fin2 inpat6m_cov_fin3 
inpat6m_cov_fin4 inpat6m_cov_fin5 inpat6m_cov_fin6 inpat6m_cov_fin7 inpat6m_cov_fin8 
inpat6m_cov_fin9) 
 
egen inclt5k_mplus=rowmax(inclt5k_cov_fin1 inclt5k_cov_fin2 inclt5k_cov_fin3 
inclt5k_cov_fin4 inclt5k_cov_fin5 inclt5k_cov_fin6 inclt5k_cov_fin7 inclt5k_cov_fin8 
inclt5k_cov_fin9) 
 
egen insur6m_mplus=rowmax(insur6m_cov_fin1 insur6m_cov_fin2 insur6m_cov_fin3 
insur6m_cov_fin4 insur6m_cov_fin5 insur6m_cov_fin6 insur6m_cov_fin7 insur6m_cov_fin8 
insur6m_cov_fin9) 
 
egen imcare6m_mplus=rowmax(imcare6m_cov_fin1 imcare6m_cov_fin2 imcare6m_cov_fin3 
imcare6m_cov_fin4 imcare6m_cov_fin5 imcare6m_cov_fin6 imcare6m_cov_fin7 
imcare6m_cov_fin8 imcare6m_cov_fin9) 
 
egen imcaid6m_mplus=rowmax(imcaid6m_cov_fin1 imcaid6m_cov_fin2 imcaid6m_cov_fin3 
imcaid6m_cov_fin4 imcaid6m_cov_fin5 imcaid6m_cov_fin6 imcaid6m_cov_fin7 
imcaid6m_cov_fin8 imcaid6m_cov_fin9) 
 
egen ipriv6m_mplus=rowmax(ipriv6m_cov_fin1 ipriv6m_cov_fin2 ipriv6m_cov_fin3 
ipriv6m_cov_fin4 ipriv6m_cov_fin5 ipriv6m_cov_fin6 ipriv6m_cov_fin7 ipriv6m_cov_fin8 
ipriv6m_cov_fin9) 
 
egen bmimedh_mplus=rowmax(bmimedh_cov_fin1 bmimedh_cov_fin2 bmimedh_cov_fin3 
bmimedh_cov_fin4 bmimedh_cov_fin5 bmimedh_cov_fin6 bmimedh_cov_fin7 
bmimedh_cov_fin8 bmimedh_cov_fin9) 
 
egen skin_final=rowtotal(evrskininfct1 evrskininfct2 evrskininfct3 evrskininfct4 evrskininfct5 
evrskininfct6 evrskininfct7 evrskininfct8 evrskininfct9 blskininfct6m1 blskininfct6m2 
blskininfct6m3 blskininfct6m4 blskininfct6m5 blskininfct6m6 blskininfct6m7 blskininfct6m8 
blskininfct6m9 skininfct6m1 skininfct6m2 skininfct6m3 skininfct6m4 skininfct6m5 
skininfct6m6 skininfct6m7 skininfct6m8 skininfct6m9) 
generate skin_mplus=skin_final 
replace skin_mplus=1 if skin_final>=1 
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replace skin_mplus=0 if skin_final==0 
 
egen hrtdx_final=rowtotal(evrhrtdx1 evrhrtdx2 evrhrtdx3 evrhrtdx4 evrhrtdx5 evrhrtdx6 
evrhrtdx7 evrhrtdx8 evrhrtdx9 blhrtdx6m1 blhrtdx6m2 blhrtdx6m3 blhrtdx6m4 blhrtdx6m5 
blhrtdx6m6 blhrtdx6m7 blhrtdx6m8 blhrtdx6m9 hrtdx6m1 hrtdx6m2 hrtdx6m3 hrtdx6m4 
hrtdx6m5 hrtdx6m6 hrtdx6m7 hrtdx6m8 hrtdx6m9) 
generate hrtdx_mplus=hrtdx_final 
replace hrtdx_mplus=1 if hrtdx_final>=1 
replace hrtdx_mplus=0 if hrtdx_final==0 
 
egen MI_final=rowtotal(evrmyoinfrct1 evrmyoinfrct2 evrmyoinfrct3 evrmyoinfrct4 
evrmyoinfrct5 evrmyoinfrct6 evrmyoinfrct7 evrmyoinfrct8 evrmyoinfrct9 blmyoinfrct6m1 
blmyoinfrct6m2 blmyoinfrct6m3 blmyoinfrct6m4 blmyoinfrct6m5 blmyoinfrct6m6 
blmyoinfrct6m7 blmyoinfrct6m8 blmyoinfrct6m9 myoinfrct6m1 myoinfrct6m2 myoinfrct6m3 
myoinfrct6m4 myoinfrct6m5 myoinfrct6m6 myoinfrct6m7 myoinfrct6m8 myoinfrct6m9) 
generate MI_mplus=MI_final 
replace MI_mplus=1 if MI_final>=1 
replace MI_mplus=0 if MI_final==0 
 
egen hrtfail_final=rowtotal(evrhrtfail1 evrhrtfail2 evrhrtfail3 evrhrtfail4 evrhrtfail5 evrhrtfail6 
evrhrtfail7 evrhrtfail8 evrhrtfail9 blhrtfail6m1 blhrtfail6m2 blhrtfail6m3 blhrtfail6m4 
blhrtfail6m5 blhrtfail6m6 blhrtfail6m7 blhrtfail6m8 blhrtfail6m9 hrtfail6m1 hrtfail6m2 
hrtfail6m3 hrtfail6m4 hrtfail6m5 hrtfail6m6 hrtfail6m7 hrtfail6m8 hrtfail6m9) 
generate hrtfail_mplus=hrtfail_final 
replace hrtfail_mplus=1 if hrtfail_final>=1 
replace hrtfail_mplus=0 if hrtfail_final==0 
 
egen stroke_final=rowtotal(evrstroke1 evrstroke2 evrstroke3 evrstroke4 evrstroke5 evrstroke6 
evrstroke7 evrstroke8 evrstroke9 blstroke6m1 blstroke6m2 blstroke6m3 blstroke6m4 
blstroke6m5 blstroke6m6 blstroke6m7 blstroke6m8 blstroke6m9 stroke6m1 stroke6m2 
stroke6m3 stroke6m4 stroke6m5 stroke6m6 stroke6m7 stroke6m8 stroke6m9) 
generate stroke_mplus=stroke_final 
replace stroke_mplus=1 if stroke_final>=1 
replace stroke_mplus=0 if stroke_final==0 
 
egen cancer_final=rowtotal(evrcancer1 evrcancer2 evrcancer3 evrcancer4 evrcancer5 evrcancer6 
evrcancer7 evrcancer8 evrcancer9 blcancer6m1 blcancer6m2 blcancer6m3 blcancer6m4 
blcancer6m5 blcancer6m6 blcancer6m7 blcancer6m8 blcancer6m9) 
generate cancer_mplus=cancer_final 
replace cancer_mplus=1 if cancer_final>=1 
replace cancer_mplus=0 if cancer_final==0 
 
egen pneuma_final=rowtotal(evrpneuma1 evrpneuma2 evrpneuma3 evrpneuma4 evrpneuma5 
evrpneuma6 evrpneuma7 evrpneuma8 evrpneuma9 blpneum6m1 blpneum6m2 blpneum6m3 
blpneum6m4 blpneum6m5 blpneum6m6 blpneum6m7 blpneum6m8 blpneum6m9 pneum6m1 




replace pneuma_mplus=1 if pneuma_final>=1 
replace pneuma_mplus=0 if pneuma_final==0 
 
egen sepsis_final=rowtotal(evrspsis1 evrspsis2 evrspsis3 evrspsis4 evrspsis5 evrspsis6 evrspsis7 
evrspsis8 evrspsis9 blsepsis6m1 blsepsis6m2 blsepsis6m3 blsepsis6m4 blsepsis6m5 blsepsis6m6 
blsepsis6m7 blsepsis6m8 blsepsis6m9 sepsis6m1 sepsis6m2 sepsis6m3 sepsis6m4 sepsis6m5 
sepsis6m6 sepsis6m7 sepsis6m8 sepsis6m9) 
generate sepsis_mplus=sepsis_final 
replace sepsis_mplus=1 if sepsis_final>=1 
replace sepsis_mplus=0 if sepsis_final==0 
 
egen endo_final=rowtotal(evrendo1 evrendo2 evrendo3 evrendo4 evrendo5 evrendo6 evrendo7 
evrendo8 evrendo9 blendo6m1 blendo6m2 blendo6m3 blendo6m4 blendo6m5 blendo6m6 
blendo6m7 blendo6m8 blendo6m9 endo6m1 endo6m2 endo6m3 endo6m4 endo6m5 endo6m6 
endo6m7 endo6m8 endo6m9) 
generate endo_mplus=endo_final 
replace endo_mplus=1 if endo_final>=1 
replace endo_mplus=0 if endo_final==0 
 
egen attempt_final=rowtotal(attempt1 attempt2 attempt3 attempt4 attempt5 attempt6 attempt7 
attempt8 attempt9) 
generate attempt_mplus=attempt_final 
replace attempt_mplus=1 if attempt_final>=1 
replace attempt_mplus=0 if attempt_final==0 
 
egen disability_mplus=rowmax(disability1 disability2 disability3 disability4 disability5 
disability6 disability7 disability8 disability9) 
 
egen heroin_mplus=rowmax(smkher_mplus snrther_mplus injher_mplus) 
egen cocaine_mplus=rowmax(injcoc_mplus snrtcoc_mplus) 
egen anydrug6m_mplus=rowmax(heroin_mplus cocaine_mplus spdbal_mplus crack_mplus) 
replace anydrug6m_mplus=1 if anydrug6m_mplus>=1 
replace anydrug6m_mplus=0 if anydrug6m_mplus==0 
replace anydrug6m_mplus=1 if curuser_mplus==1 
 
egen newdrugvar=rowtotal(anydrug6m_mplus curuser_mplus) 
replace newdrugvar=2 if curuser_mplus==1 
 
gen drug_none=. 
replace drug_none=1 if newdrugvar==0 
replace drug_none=0 if drug_none==. 
 
gen drug_noninj=. 
replace drug_noninj=1 if newdrugvar==1 





replace drug_inj=1 if newdrugvar==2 




egen event_id=rowmax(pneuma_mplus endo_mplus sepsis_mplus skin_mplus) 
egen event_cvd=rowmax(stroke_mplus hrtfail_mplus MI_mplus hrtdx_mplus) 
 
 
foreach var of varlist _all { 




keep id diabetic_final htn_final ob_air2_final renal_final  arthritis_final ad_stringent_final  
major_psych_final fibrosis_mplus ipriv6m_mplus imcaid6m_mplus imcare6m_mplus 
insur6m_mplus inclt5k_mplus outpat_mplus er6m_mplus samedocx_mplus ost_mplus 
abusecr_mplus curuser_mplus injher_mplus snrther_mplus smkher_mplus spdbal_mplus 
injcoc_mplus snrtcoc_mplus crack_mplus mj_mplus alcyn_mplus cigyn_mplus black_mplus 
m0f1_mplus age_mplus disability_mplus anydrug6m_mplus event_id event_cvd depress2 


























Codebook for Qualitative Data  
 
1.0 Current Life Current life events in response to question 1  
2.0 Enabling Factors Enabling factors that act as facilitators and barriers to engagement in care 
2.1 EF_Current HC Reason 
and Location Reason why and where they went for healthcare including transportation 
2.2 EF_Current HC Staff Experience with non-medical staff where they seek care  
2.3 EF_Current HC Providers Experience with medical staff where they seek care 
2.4 EF_Care team facilitators Discussion about how Medical and Non-medical staff help their care 
2.5 EF_Care team barriers Discussion about how Medical and Non-medical staff impede their care 
2.6 EF_Financial facilitators Discussion about how insurance, copay, or other monetary costs help their care 
2.7 EF_Financial barriers Discussion about how insurance, copay, or other monetary costs impede their care 
2.8 EF_Social facilitators Discussion about how social network helps their care 
2.9 EF_Social barriers Discussion about how social network imedes their care 
3.0 Need Factors Factors that relate to health care needs, including preceived and actual need 
3.1 NF_ Being Healthy Descriptions of what being healthy means to the participant 
3.2 NF_ Healthy Needs Details about what the participant needs to achieve their healthy construct 
3.3 NF_ Health concerns Description of major health concerns  
3.4 NF_ Chronic Dx Health Description of health needs concerning a specific of multiple diseases (code with a disease) 
3.5 NF_ Chronic Dx barriers Barriers that prevent participant from managing specific chronic diseases (code with a disease) 
3.6 NF_ HC Satisfaction Description of satisfaction with health care 
3.7 NF_ HC Satifaction Needs Health care addressing their needs 
3.8 NF_ HC Satisfaction 
Improve Descriptions of how to better meet health needs and improve satisfaction 
4.0 Substance Use Health 
Behaviors Health Behaviors/Practices related to substance use and their relationship to engagment in care 
4.1 SU_ Health professionals 
engage Impact of health professions on staying engaged in care for substance use recovery/management, including SU reduction 
4.2 SU_Harm reduction  
Engagement in harm reduction including using clean needles, testing their drug supply, knowing their dealer, using 
condoms, etc.  
4.3 SU_Motivations Non medical or personal motivating factors related to substance use management 
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4.4 SU_Deterrents Non medical or personal factors that discourage or hinder substance use management 
4.5 SU_Future behaviors References to behaviors participants will undertake to reduce substance use  
4.6 SU_ Future services References to services participants will access to reduce substance use  
4.7 SU_Advice Advice or feedback on what health professionals and patients could do to engage participants in Substance Use recovery  
5.0 Chronic Disease Health 
Behaviors Health Behaviors/Practices related to chronic disease management and their relationship to engagment in care 
5.1 CD_Health professionals 
engage Impact of health professionals on staying engaged in care for chronic disease management 
5.2 CD_Motivations Non medical or personal motivating factors related to chronic disease management 
5.3 CD_Deterrents Non medical or personal factors that discourage or hinder chronic disease management 
5.4 CD_Future behaviors References to behaviors participants will undertake to achieve their optimal health for chronic diseases 
5.5 CD_ Future services References to services participants will seek for chronic disease management 
5.6 CD_Advice Advice or feedback on what health professionals and patients could do to engage participants in chronic disease care 
6.0 Safe Consumption Space Discussion about thoughts on the implentation of a safe consumption space. 
6.1 SCS_Barriers  Discussion about potential barriers and drawback to creating a Safe Consumption Space 
6.2 SCS_Facilitator Discussion about potential facilitators and benefits to creating a Safe Consumption Space  
HIV   
Hepatitis C   
Diabetes   
Hypertension   
Pain Management   
Mental Health    
Medications   
Medication for Opioid Use 
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